

47. Iron-Overload and Chemotherapy-Related Adverse Events in Pediatric Cancer Patients. Elly V. Barry, MD – Fellow in Pediatric Hematology-Oncology, Dana-Farber Cancer Institute/Children’s Hospital Boston. Harvard Medical School, Scholars in Clinical Science Program (NIH K-30) leading to a MMS in May 2007 in Clinical Investigation. Several papers – 2 first author in Expert Opinion in Pharmacotherapy (2007) and Journal of Clinical Oncology in 2008. Several grants – NCI-2 grants, Leukemia and Lymphoma Society, and Lance Armstrong Foundation. Several research protocols. Currently Instructor in Pediatrics and Attending Physician, Pediatric Hematology-Oncology, Dana-Farber Cancer Institute. Dr. Lipshultz on K-23 advisory committee.
48. Pediatric Oncology Late Effects. David Landy, MPH – MD-PhD candidate, University of Miami Miller School of Medicine. Dr. Lipshultz is on his committee. By January 2010 David had a chapter as an author and 3 abstracts submitted – three as first author. As of July 2011 David was PI on an AHA grant and was awaiting results of an NIH grant he is PI on.
49. Energy Drink Health Effects in Children, Adolescents, and Young Adults. Sara Seifert, BS. Medical Student. University of Miami Miller School of Medicine. First author of Special Article in Pediatrics, first author of late breaker abstract to Pediatric Academic Society meeting in 2011. Two other papers and abstracts as well.

MEMBER, THESIS/DISSERTATION GRADUATE SCHOOL COMMITTEES:

1. Leotien Carola Maria Kremer, MD. (2001). PhD Dissertation Committee, University of Amsterdam. “Anthracycline cardiotoxicity in childhood cancer: frequency, risk factors, and early detection.” Amsterdam, The Netherlands. (invited)
2. Heleen J. H. van der Pal, MD. (2002-4). PhD Dissertation Committee, University of Amsterdam. “Late effects of childhood cancer.” Amsterdam, The Netherlands. (invited)
3. Michael Jacob Adams, MD. (2002-2003). MPH in Clinical Investigation and the Rochester Clinical Research Curriculum Thesis Committee, University of Rochester. “Cardiovascular function in long-term survivors of Hodgkin’s disease treated with chest radiotherapy.” Rochester, NY.
4. Michael Jacob Adams, MD (2003-current). NIH K-23 Advisory Committee Member. University of Rochester. “Radiation late effects and cancer and cardiac consequences.” Rochester, NY.
5. Jorge A. Alvarez (2005-current). MD-PhD Candidate. PhD in Epidemiology (C00-15-7098). Member of a Committee to supervise the Doctoral Dissertation (Ph.D.). University of Miami. “Baseline predictors of outcome in pediatric dilated cardiomyopathy.” Miami, FL. This was successfully defended on July 1, 2009.
6. Elly V. Barry, MD (2007-current). NCI K-23 (Mentored Patient-Oriented Career Development Award to Promote Diversity) Advisory Committee Member. Dana-Farber Cancer Institute, Children’s Hospital Boston, and Harvard Medical School. “Iron-overload and chemotherapy-related adverse events in pediatric cancer patients.” Boston, MA. (Left for industry -2008).
7. Sanjeev Sirpal (2008-2008). MD-PhD Candidate. PhD in Molecular and Cellular Pharmacology. Member of a Committee to supervise the Doctoral Dissertation (Ph.D.). University of Miami. “HCTnT4 up-regulation in heart disease: mechanistic insight into the functional significance of differential cardiac troponin T isoform expression.” University of Miami. Miami, FL. (Candidate Inactive – 2008).
8. Jacqueline D. Peacock (2008-2011). PhD in Molecular and Cellular Pharmacology (C04-61-0926). Member of a Committee to supervise the Doctoral Dissertation (Ph.D.). “The role of Sox9 in development and maintenance of heart valve connective tissue.” Successfully completed in May 2011 with a PhD awarded. University of Miami. Miami, FL.

9. Johanna Lopez (2008-2009). PhD Candidate in Molecular and Cellular Pharmacology. Member of a Committee to supervise the Doctoral Dissertation (Ph.D.). Scheduled to receive a terminal Master of Science degree in December 2009 at her request. Thesis Title: "The MAKAP-beta signalosome is involved in cardiac myocyte hypertrophy through the recruitment of calcineurin A-beta: A study on how multimolecular complexes are important for the integration and fidelity of signal transduction behind cellular and physiological responses." Mentor: Michael Kapiloff. University of Miami. Miami, FL.
10. David Cooper Landy (2009-current). MD-PhD Candidate in Epidemiology. Member of a Committee to supervise the Doctoral Dissertation (PhD). Thesis Title: "Late effects after childhood cancer." University of Miami. Miami, FL.
11. Margaret Benny Klimek (2010-current). PhD Candidate in Molecular Cell and Developmental Biology (C04-97-5957). Member of a Committee to supervise the Doctoral Dissertation (PhD). "Molecular mechanisms of Sox9 in heart valve development." University of Miami. Miami, FL.
12. Michael Kritzer-Cheren (2010-current). PhD Candidate in Molecular and Cellular Pharmacology. Member of a Committee to supervise the Doctoral Dissertation (PhD). "The regulation of cardiac myocyte cAMP levels by the Adenylyl Cyclase Type 5 (AC5)-muscle A-Kinase Anchoring Protein (mA-KAP) complex." (AHA Predoctoral Fellowship). University of Miami, Miami, FL.

PRINCIPAL CLINICAL AND HOSPITAL SERVICE RESPONSIBILITIES:

1. Attending, Cardiology Consult Service, Children's Hospital, Boston - 1988-1996.
2. Attending, Cardiology Clinic, Children's Hospital, Boston - 1988-1996.
3. Attending, Cardiology Medical Service, Children's Hospital, Boston - 1988-1996.
4. Consultant, Pediatric Oncology Late Effects Clinic, Dana-Farber Cancer Institute - 1991-1996.
5. Director, Pediatric Cardiology Clinic, Boston City Hospital - 1988-1996.
6. Director, Pediatric Cardiology Consult Service, Boston City Hospital - 1988-1996.
7. Director, Pediatric Electrocardiography/Echocardiography, Boston City Hospital - 1988-1996.
8. Member, Executive Committee, Department of Pediatric, University of Rochester - 1996-2003.
9. Member, Finance Committee, Department of Pediatrics, University of Rochester - 1996-2003.
10. Member, Research Committee, Department of Pediatrics, University of Rochester - 1996-2003.
11. Member, Chief of Adult Cardiology Search Committee, University of Rochester - 1996 - 1998.
12. Attending, Pediatric Cardiology Inpatient Service, Children's Heart Center at Strong - 1997-2003.
13. Attending, Pediatric Cardiology Clinic, Children's Heart Center at Strong - 1997-2003.
14. Director, Pediatric Cardiomyopathy Program, Children's Heart Center at Strong - 1997-2003.
15. Director, Pediatric Preventive Cardiol Program, Children's Heart Center at Strong - 1997-2003.
16. Member, Task Force on Group Practice, Department of Pediatrics, University of Rochester - 1997.
17. Co-chair, Task Force on Fellowships, Department of Pediatrics, University of Rochester - 1997.
18. Member, Pediatric Health Outcomes Methodologist Search Committee, Department of Pediatrics, University of Rochester - 1997.
19. Member, Task Force on Compensation and Accountability, Department of Pediatrics, University of Rochester - 1997 - 1998.
20. Member, Task Force on Critical Care, Department of Pediatrics, University of Rochester - 1997-1998.
21. Member, Task Force on Cardiac Transplantation, University of Rochester - 1997 - 1999.
22. Member, Cardiology Core Committee, University of Rochester - 1997 - 1999.
23. Member, Task Force on Cardiac Catheterization Labs, University of Rochester - 1998-1999.
24. Member, Ad Hoc Committee on Faculty Promotion, University of Rochester - 1999-2000.
25. Co-Chair, Task Force on The Strong Children's Research Center, University of Rochester - 2000.

26. Faculty, University of Rochester Pediatric Critical Care Fellowship Program (ACGME-accredited) – 1996-2003.
27. Faculty, University of Rochester Pediatric Cardiology Fellowship Program (ACGME-accredited) – 1996-2003.
28. Co-chair, Search Committee for Chief of Pediatric Genetics, Golisano Children's Hospital at Strong – 2001-2003.
29. Co-chair, Pediatric Cardiac Intensive Care Unit User Group Planning Committee – 2002-2003.
30. Member, Search Committee for Chief of Pediatric Hematology/Oncology, Golisano Children's Hospital at Strong – 2002-2003.
31. Member, Chief of Adult Cardiology Search Committee, University of Rochester - 2002 - 2003.
32. Member, Oncology Translational Research Scientist Search Committee, University of Rochester - 2002 - 2003.
33. Member, Pediatric Intensive Care Unit Program Management Group, University of Rochester – 2002 – 2003.
34. Member, Pediatric Grants Office Review Committee, University of Rochester - 2002.
35. Member, Ad-hoc Faculty Promotion Committee, University of Rochester - 2003.
36. Member, Dean's Small Group Meeting, University of Miami School of Medicine – 2003-2004.
37. Member, Clinical Chair's Group Meeting, University of Miami School of Medicine – 2003-current.
38. Member, University of Miami Medical Group Governing Board – 2003-current.
39. Member, University of Miami Medical Group Executive Committee – 2003-current.
40. Member, University of Miami Medical Group Business Development and Strategic Committee – 2003-current.
41. Member, Capital Assets Committee, Jackson Memorial Medical Center – 2004-2006.
42. Member, Medical Executive Committee, Jackson Memorial Medical Center – 2003-current.
43. Member, Clinical Chiefs-of-Service Meeting, Jackson Memorial Medical Center – 2003-current.
44. Director, Pediatric Executive Committee Meeting, University of Miami School of Medicine – 2003-current.
45. Director, Pediatric Faculty Meeting, University of Miami School of Medicine – 2003-current.
46. Member, Clinical Research Institute Planning Group, University of Miami School of Medicine – 2004-2006.
47. Secretary-Treasurer, Medical Executive Comm, Jackson Memorial Medical Ctr – 2004-current.
48. Member, Steering Committee, Sylvester Comprehensive Cancer Center – 2004-current.
49. Member, Clinical Practice Committee, Jackson Memorial Medical Center – 2004-current.
50. Member, Fiscal Affairs, Purchasing and Budget Committee, Public Health Trust Board of Trustees, Jackson Health System, Miami – 2005-current.
51. Member, Underwriting Committee, University of Miami Medical Group -2005-current
52. Member, Executive Committee, University of Miami Medical Group – 2005-current
53. Member, Steering Committee, Clinical Research Task Force, University of Miami School of Medicine – 2005-2006.
54. Member, Search Committee for a New Dean of the Miller School of Medicine and Senior Vice President for Health Affairs of the University of Miami – 2005-2006
55. Member and Co-Chair, Miami Children's Hosp Academic Affiliation Task Force – 2005-2007.
56. Member, Dean's Operations Leadership Group, University of Miami Miller School of Medicine – 2006-current.
57. Member, Research Leadership Group Cabinet, University of Miami Miller School of Medicine – 2006-current.

58. Member, Search Committee for a Chair of the Department of Medicine, University of Miami Miller School of Medicine – 2006-2007.
59. Member, Dean's Executive Comm, University of Miami Miller School of Med – 2007-current.
60. Member, Board of Governors, Self-insurance (SIR) Committee, University of Miami Medical Group – 2007-current.
61. Member, Miami Transplant Institute Board of Governors – 2007-current.
62. Member, Dean's Quarterly Medical School Executive Group – 2007-current.
63. Member, University of Miami Miller School of Medicine-Jackson Memorial Hospital Leadership Committee Group – 2008-current.
64. Member, Patient Safety and Risk Management Leadership Group. – 2008-current.
65. Member, Search Committee for a Division Director of Biostatistics, Department of Epidemiology, University of Miami Miller School of Medicine – 2008-2009.
66. Chair, Search Committee for a New Chair of the Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine – 2008-2009.
67. Member, University of Miami Miller School of Medicine LCME Committee on Administration and Governance – 2008-current.
68. Member, Miami Transplant Institute Transplant Emergency/Advisory Panel, Transplant Institute at Jackson Memorial Hospital and the University of Miami Miller Sch of Med - 2008-current.
69. Member, Task Force on Psychiatry Committee – 2008-2009.
70. Member, University of Miami Medical Group Finance Committee – 2009-current.
71. Member, Press-Ganey User Group, University of Miami Medical Group – 2009-current.
72. Member, UCare Steering Committee – 2009-current.
73. Member, University of Miami/Jackson Health System Committee Task Force Annual Operating Agreement Committee – 2010-current.
74. Member, University of Miami Sylvester Comprehensive Cancer Center Director Search Committee – 2010-current.
75. Member, University of Miami Miller School of Medicine Department of Molecular and Cellular Pharmacology Cardiac Section Faculty Search Committee – 2010-current.
76. Member, Children's Hospital Operations Oversight Standing Committee. Public Health Trust Board of Trustees, Jackson Health System, Miami – 2008-current.
77. Member, Ad Hoc Committee on International Health Affairs. Public Health Trust Board of Trustees, Jackson Health System, Miami – 2010-current.
78. Member, UHealth Committee on Conflicts of Interest – 2011-current.
79. Member, University of Miami Comparative Effectiveness Research Group-2011-current.

MAJOR ADMINISTRATIVE RESPONSIBILITIES:

1. Director – Center for the Study of Pulmonary and Cardiac Manifestations of Pediatric HIV Infection. A collaborative study at Children's Hospital, Boston, Brigham and Woman's Hospital, Beth Israel Hospital, Boston City Hospital and the Harvard School of Public Health. As principal investigator Dr. Lipshultz directed this \$9.9 million, 10 year, NIH-sponsored program and supervised the work of a staff of 30. 1989-1999. Reviewed in Pediatric AIDS Newsletter Vol. 3, #6, 9/92 (<http://www.aidsinforbbs.org/periodicals/pediatric.36>).
2. Director, Pediatric Cardiology, Boston City Hospital (from 1988 until 1/1/96)
3. Director, Cardiomyopathy Working Group, Children's Hospital, Boston (until 12/96).
4. Coordinator, Pediatric HIV Clinical Studies Conference, Children's Hospital, Boston (until 8/96).
5. Director, Infants' and Children's AIDS Relief Effort – The I CARE Program. (Until 12/96)
6. Director, Purity Literacy Program. (Until 12/96)

7. Chief, Division of Pediatric Cardiology, University of Rochester (From 12/1/06 until 8/14/03)
8. Chairman, Department of Pediatrics, University of Miami Miller School of Medicine since August 15, 2003
9. Chief-of-Staff, Holtz Children's Hospital (HCH)/Jackson Memorial Medical Center – Miami, FL
10. Director, University of Miami Pediatric Clinical Practice
11. Director of Pediatric Patient Protection and Risk Prevention at the University of Miami
12. Associate Executive Dean of Child Health. University of Miami Miller School of Medicine
13. Director, University of Miami Children's Health Institutes
14. National Advocacy Activities as Chair of Pediatrics at the University of Miami

PUBLICATIONS:

Papers:

1. **Lipshultz S**, Shanfeld J, Chacko S. Emergence of beta-adrenergic sensitivity in the developing chicken heart. *Proc Natl Acad Sci USA* 78:288-94 (1981) PMID: 6113587
2. **Lipshultz S**, Sanders SP, Mayer J, Colan SD, Lock JE. Are cardiac catheterization and angiography necessary in the preoperative evaluation of ASD-primum? *J Am Coll Cardiol* 11:373-8 (1988) PMID: 3339177
3. **Lipshultz S**, Chanock S, Sanders SP, Colan SD, McIntosh K. Cardiovascular manifestations of human immunodeficiency infection in infants and children. *Am J Cardiol* 63:1489-97 (1989) PMID: 2729137
4. Goorin AM, Chauvenet AR, Perez-Atayde AR, Cruz J, McKone R, **Lipshultz SE**. Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer. *J Pediatr* 116:144-147 (1990) PMID: 2295956
5. **Lipshultz SE**, Fox CH, Perez-Atayde AR, Sanders SP, Colan SD, McIntosh K, Winter HS. Identification of human immunodeficiency virus-1 RNA and DNA in the heart of a child with cardiovascular abnormalities and congenital acquired immune deficiency syndrome. *Am J Cardiol* 66:246-250 (1990) PMID: 2371963
6. **Lipshultz SE**, Frassica JJ, Orav EJ. Cardiovascular abnormalities in infants prenatally exposed to cocaine. *J Pediatr* 118:44-52 (1991) PMID: 1986097
7. **Lipshultz SE**, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin in childhood acute lymphoblastic leukemia. *N Engl J Med* 324:808-15 (1991). PMID: 1997853
• Featured with an editorial.
8. Braverman RM, **Lipshultz SE**, McCarten KM, Griscom NT. Cardiac hemangioma. *RadioGraphics* 11:932-4 (1991) PMID: 1947327
9. **Lipshultz SE**, Orav EJ, Sanders SP, Rubin A, McIntosh K, Colan SD. Abnormalities of cardiac structure and function in HIV-infected children treated with zidovudine. *N Engl J Med* 327:1260-5 (1992). PMID: 1406818
10. **Lipshultz SE**, Sanders SP, Colan SD. Cardiac structure and function in HIV-infected children (letter). *N Engl J Med* 328:513-4 (1993). PMID: 8421484
11. Luginbuhl LM, Orav EJ, McIntosh K, **Lipshultz SE**. Cardiac morbidity and related mortality in children with symptomatic HIV infection. *J Am Med Assoc* 269:2869-2875 (1993). PMID: 8388521
12. **Lipshultz SE**, Sallan SE. Cardiovascular abnormalities in long-term survivors of childhood cancer (commentary). *J Clin Oncol* 11:1199-1203 (1993). PMID: 8315417
13. Shearer WT, Rosenblatt HM, Schluchter MD, Mofenson LM, Denny TN, the NICHD IVIG Clinical Trial Group, and the NHLBI P²C² Pediatric Pulmonary and Cardiac

- Complications of HIV Infection Study Group.** Immunologic Targets of HIV Infection: T Cells. *Ann N Y Acad Sci* 693:35-51 (1993). PMID: 7903519
14. Chanock S, Luginbuhl LM, McIntosh K, **Lipshultz SE.** Life-threatening reactions to trimethoprim-sulfamethoxazole in children with HIV infection. *Pediatrics* 93:519-21 (1994). PMID: 8115221
 15. **Lipshultz SE,** Sanders SP, Goorin A, Krischer JP, Sallan SE, Colan SD. Monitoring for anthracycline cardiotoxicity. *Pediatrics* 93:433-437 (1994). PMID: 7818624
 16. **Lipshultz SE,** Orav EJ, Sanders SP, McIntosh K, Colan SD. Limitations of fractional shortening as an index of contractility in HIV-infected children. *J Pediatr* 125:563-70 (1994). PMID: 7931874
 17. Frassica JJ, Orav EJ, Walsh EP, **Lipshultz SE.** Arrhythmias in children prenatally exposed to cocaine. *Arch Pediatr Adol Med* 148:1163-1169 (1994). PMID: 7921117
 18. **Lipshultz SE,** Sanders SP, Goorin AM, Krischer J, Sallan SE, Colan SD. The Anthracycline Cardiotoxicity Debate (letter). *Pediatrics* 94:781-2 (1994). PMID: 7936925
 19. Kaplan S, **Lipshultz SE.** Cardiovascular complications of HIV infection in children. *Cardiol Rev* 3:99-105 (1995).
 20. Lane-McAuliffe EA, **Lipshultz SE.** Cardiovascular manifestations of pediatric HIV infection. *Nurs Clin N Amer* 30:291-316 (1995). PMID: 7777409
 21. **Lipshultz SE,** Lipsitz S, Goorin AM, Sallan SE, Mone SM, Sanders SP, Orav EJ, Gelber RD, Colan SD. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. *N Engl J Med* 332:1738-43 (1995). PMID: 7760889
 22. **Lipshultz SE,** Orav EJ, Sanders SP, Colan SD. Immunoglobulins and cardiac structure and function in HIV-infected children. *Circulation* 92:2220-2225 (1995). PMID: 7554205
 23. Marin-Garcia J, Goldenthal MJ, Ananthakrishnan R, Pierpont MEM, Fricker FJ, **Lipshultz SE,** Perez-Atayde A. Specific mitochondrial DNA deletions in idiopathic dilated cardiomyopathy. *Cardiovascular Research* 31:306-13 (1996). PMID: 8730408
 24. Marin-Garcia J, Goldenthal MJ, Ananthakrishnan R, Pierpont MEM, Fricker FJ, **Lipshultz SE,** Perez-Atayde A. Mitochondrial function in children with idiopathic dilated cardiomyopathy. *J Inherited Metabolic Disease* 19:309-12 (1996). PMID: 8803773
 25. Kattan M, Beck G, Kaplan S, **Lipshultz S,** Mellins R, Moodie D, Peavy H, Schluchter M, Shearer W, Weinstein C, Wu M. The pediatric pulmonary and cardiovascular complications of vertically transmitted human immunodeficiency virus (P²C² HIV) infection study: Design and methods. *J Clin Epidemiol* 49:1285-94 (1996). PMID: 8892497
 26. Schwartz ML, Cox GF, Lin AE, Korson MS, Perez-Atayde A, Lacro RV, **Lipshultz SE.** Clinical approach to genetic cardiomyopathy in children. *Circulation* 94:2021-38 (1996). PMID: 8873681
 27. **Lipshultz SE.** Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children (commentary). *J Clin Oncol* 14:328-331 (1996). PMID: 8636739
 28. Epstein JE, Eichbaum QG, **Lipshultz SE.** Cardiovascular manifestations of HIV infection. *Comprehensive Therapy* 22(8):485-91 (1996). PMID: 8879915
 29. Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, **Lipshultz SE.** Clinical cardiotoxicity following anthracycline treatment for childhood cancer: The pediatric oncology group experience. *J Clin Oncol* 15:1544-52 (1997). PMID: 9193351
 30. Martin RJ, Boyer P, Hammill H, Peavy H, Platzker A, Settlage R, Shah A, Sperling R, Tuomala R, Wu M, **P²C² HIV Study Group.** Incidence of premature birth and neonatal respiratory disease in infants of HIV positive mothers. *J Pediatr* 131:851-6 (1997). PMID: 9427889

31. Miller TL, Orav EJ, Colan SD, **Lipshultz SE**. Nutritional status and cardiac mass and function in children infected with the human immunodeficiency virus. *Am J Clin Nutr* 66:660-4 (1997). PMID: 9280189
32. **Lipshultz SE**, Rifai N, Sallan SE, Lipsitz SR, Dalton V, Sacks DB, Ottlinger ME. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. *Circulation* 96:2641-2648 (1997). PMID: 9355905
 - Featured with an editorial.
33. **Lipshultz SE**, Grenier M. Left ventricular function in infants and children infected with the human immunodeficiency virus. *Progress in Pediatric Cardiology* 7:33-43 (1997).
34. Cleveland RH, Schluchter M, Wood BP, Berdon WE, Boechat I, Easley KA, Meziane M, Mellins RB, Norton KI, Singleton E, Trautwein L, **P²C² HIV Study Group**. Chest radiographic data acquisition and quality assurance in multicenter studies. *Pediatr Radiol* 27:880-887 (1997). PMID: 9361051
35. Cohen H, Carp D, Davis L, Geromanos K, Hunter J, Sunkle S, **P²C² HIV Study Group**. Coordinating the large multicentered HIV research project. *J Assoc Nurs AIDS Care* 8:41-50 (1997). PMID: 9085248
36. Pitt J, Goldfarb J, Schluchter M, Kovacs A, Cooper E, Hodes D, McIntosh K, Peavy H, Shearer W, **P²C² HIV Study Group**. HIV vertical transmission rate determinations are subject to differing definitions and therefore different rates. *J Clin Epidemiol* 51:159-164 (1997). PMID: 9474076
37. Nysom K, Holm K, Lipsitz SR, Mone SM, Olsen J, Hertz H, Colan SD, Sallan SE, Orav EJ, Jacobsen JR, **Lipshultz SE**. The relation between cumulative anthracycline dose and late cardiotoxicity in survivors of childhood leukemia. *J Clin Oncol* 16:545-550 (1998). PMID: 9469339
38. Grenier MA, **Lipshultz SE**. Epidemiology of anthracycline cardiotoxicity in children and adults. *Semin Oncol* 25(suppl 10):72-85 (1998). PMID: 9768828
39. **Lipshultz SE**, Easley KA, Orav EJ, Kaplan S, Starc TJ, Bricker JT, Lai WW, Moodie DS, McIntosh M, Colan SD for the Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection Study Group. Cardiac structure and function in children infected with human immunodeficiency virus. The prospective P²C² HIV multicenter study. *Circulation* 97:1246-1256 (1998). PMID: 9570194
40. Lai WW, **Lipshultz SE**, Easley K, Starc T, Drant, S, Kaplan S, Bricker JT, Moodie D, Sopko G, Colan SD, for the P²C² Study Group. Prevalence of cardiovascular malformations in children of HIV-infected mothers: The prospective P²C² HIV multicenter study. *J Am Coll Cardiol* 32:1749-55 (1998). PMID: 9822105
41. Giantris A, Abdurrahman L, Hinkle A, Asselin B, **Lipshultz SE**. Anthracycline induced cardiotoxicity. *Critical Reviews in Oncology/Hematology*. 27:53-68 (1998). PMID: 9548017
42. Herman EH, **Lipshultz SE**, Rifai N, Zhang J, Papoian T, Yu Z-X, Ferrans VJ. Cardiac troponin T: Elevated serum levels and loss from cardiac myocytes in doxorubicin toxicity. *Cancer Research* 58:195-197 (1998). PMID: 9443390
43. Xanthos G, Carp D, Geromanos K, **P²C² HIV Study Group**. Recognizing nurses' contributions to the clinical research process. *J Assoc Nurs AIDS Care*. 9:39-48 (1998). PMID: 9436166
44. Ottlinger M, Pearsall L, Rifai N, **Lipshultz SE**. New developments in the biochemical assessment of myocardial injury in children: Troponin T and I as highly sensitive and specific markers of myocardial injury. *Progress in Pediatric Cardiology* 8:71-81 (1998).

45. Nysom K, Colan SD, **Lipshultz SE**. Late cardiotoxicity following anthracycline therapy for childhood cancer. *Progress in Pediatric Cardiology* 8(3):121-138 (1998).
46. Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, **Lipshultz SE**. Risk factors for early anthracycline cardiotoxicity in children: the pediatric oncology group experience. *Progress in Pediatric Cardiology* 8:83-90 (1998).
47. Cameron EH, **Lipshultz SE**, Tarbell NJ, Mauck PM. Cardiovascular disease in long-term survivors of pediatric Hodgkin's disease. *Progress in Pediatric Cardiology* 8:139-144 (1998).
48. **Lipshultz SE**. Dilated cardiomyopathy in HIV-infected patients (Editorial). *N Engl J Med* 339:1153-5 (1998). PMID: 9770563
49. Pitt J, Schluchter M, Jenson H, Kovacs A, LaRussa P, McIntosh K, Boyer P, Cooper E, Goldfarb J, Hammill H, Hodes D, Peavy H, Sperling R, Tuomala R, Shearer W, **The P²C² Study Group**. Maternal and perinatal factors related to maternal-infant transpission of HIV-1 in the P²C² HIV study: The role of EBV shedding. *J Acquired Immune Deficiency Syndromes* 19:462-470 (1998). PMID: 9859959
50. Starc TJ, **Lipshultz SE**, Kaplan S, Easley K, Bricker JT, Colan SD, Lai WW, Gersony WM, Sopko G, Moodie DS, Schluchter M, for the P²C² HIV study group. Cardiac complications in children with human immunodeficiency virus infection. *Pediatrics* 104:2, e14 (9 pages, URL: <http://www.pediatrics.org/cgi/content/full/104/2/e14>; HIV, cardiac disease, pediatrics) (1999). PMID: 10429132
51. Bowles NE, Kearney D, Ni J, Perez-Atayde AR, Kline MW, Bricker JT, Ayres NA, **Lipshultz SE**, Shearer WT, Towbin JA. The detection of viral genomes by polymerase chain reaction in the myocardium of pediatric patients with advanced HIV disease. *J Am Coll Cardiol* 34:857-65 (1999). PMID: 10483970
52. Starc T, Langston C, Goldfarb J, Colin A, Cooper E, Easley K, Sunkle S, and Schluchter M, **The P²C² HIV Study Group**. Unexpected non-HIV causes of death in children born to HIV-infected mothers. *Pediatrics* (104:1, e6 – 4 pages) (URL: <http://www.pediatrics.org/cgi/content/full/104/1/e6>) (1999). PMID: 10390292
53. Jenson H, McIntosh K, Pitt J, Husak S, Tan M, Bryson Y, Easley K, Shearer W, **The P²C² HIV Study Group**. Natural history of primary Epstein-Barr Virus infection in children of mothers infected with human immunodeficiency virus type 1. *Journal of Infectious Diseases* 179;1395-1404 (1999). PMID: 10228060
54. Alderson PO, Chen DCP, Fleishman MJ, Hoh CK, Kim CK, Lee VW, Mellins RB, Miller JH, Moore WH, Peavy HH, Shah A, Treves ST, **The P²C² HIV Study Group**. Radioaerosol scintigraphy in infants and children born to mothers with HIV disease. *Radiology* 210:815-22 (1999). PMID: 10207486
55. **Lipshultz SE**, Grenier MA, Colan SD. Doxorubicin-induced cardiomyopathy (letter). *N Engl J Med* 340:653-4 (1999). PMID: 10049085
56. Read JS, for the **P²C² Study Group** and the International Perinatal HIV Group. Mode of delivery and vertical transmission of HIV-1: A meta-analysis from fifteen prospective cohort studies. *N Engl J Med* 340:977-987 (1999). PMID: 10099139
57. Towbin JA, **Lipshultz SE**. Genetics of neonatal cardiomyopathy. *Curr Opin Cardiol.* 14:250-62 (1999). PMID: 10358797
58. Herman EH, Zhang J, **Lipshultz SE**, Rifai N, Chadwick D, Takeda, Yu Z-X, Ferrans VJ. Correlation between serum levels of cardiac troponin –T and the severity of chronic cardiomyopathy induced by doxorubicin. *J Clin Oncol* 17:2237-2243 (1999). PMID: 10561281
59. Miller TL, **Lipshultz SE**. Dilated cardiomyopathy in HIV-infected patients (letter). *N Engl J Med* 340:734-5 (1999). PMID: 10068328

60. Morrow GR, Hickok JT, DuBeshter B, **Lipshultz SE**. Changes in clinical measures of autonomic nervous system function related to cancer chemotherapy induced nausea. *J of the Autonomic Nervous System* 78:57-63 (1999). PMID: 10589824
61. Kovacs A, Schluchter M, Easley K, Demmler G, Shearer W, La Russa P, Pitt J, Cooper E, Goldfarb J, Hodes D, Kattan M, McIntosh K, **The P²C² HIV Study Group**. Cytomegalovirus infection and HIV-1 disease progression in infants born to HIV-1-infected women. *N Engl J Med* 341:77-84 (1999). PMID: 10395631
62. Shearer WT, **Lipshultz SE**, Easley K, McIntosh K, Pitt J, Quinn TC, Kattan M, Goldfarb J, Cooper E, Bryson Y, Kovacs A, Bricker JT, Peavy H, Mellins RB, P²C² Study Group. Alterations in cardiac and pulmonary function in pediatric rapid human immunodeficiency virus type 1 disease progressors. *Pediatrics* 2000;105(1):1-8. URL: <http://www.pediatrics.org/cgi/contents/full/105/1/e9>. PMID: 10617746
63. Hornberger LK, **Lipshultz SE**, Easley KA, Colan SD, Schwartz M, Kaplan S, Starc TJ, Ayres NA, Lai WW, Moodie DS, Kasten-Sportes C, Sanders SP, for the P²C² Study Group. Cardiac structure and function in fetuses of mothers infected with HIV: The prospective P²C²HIV multicenter study. *Am Heart J* 140:575-584 (2000). PMID: 11011330
64. Moran AM, **Lipshultz S**, Rifai N, O'Brien P, Mooney H, Perry S, Lipsitz SR, Perez-Atayde A, Colan SD. Non-invasive assessment of rejection in pediatric heart transplant patients: Serologic and echocardiographic prediction of biopsy proven myocardial rejection. *J Heart Lung Transplantation* 19:756-764 (2000). PMID: 10967269
65. Chiang VW, Burns JP, Rifai N, **Lipshultz SE**, Adams MJ, Weiner DL. Cardiac toxicity of intravenous terbutaline for the treatment of severe asthma in children: A prospective assessment. *J Pediatr* 137:73-7 (2000). PMID: 10891825
66. Platzker ACG, Colin AA, Chen XC, Hiatt P, Hunter J, Koumbourlis AC, Schluchter MD, Ting A, Wohl ME, **The P²C² HIV Study Group**. Thoracoabdominal compression and respiratory system compliance in HIV-infected infants. *Amer J Respir Crit Care Med*. 161:1567-1571 (2000). PMID: 10806156
67. **Lipshultz SE**, Easley KA, Orav EJ, Kaplan S, Starc TJ, Bricker JT, Lai WW, Moodie DS, Colan SD for the Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection Study Group. Cardiac dysfunction and mortality in HIV-infected children. The prospective P²C² HIV multicenter study. *Circulation* 102:1542-1548 (2000). PMID: 11182983
68. Grenier MA, Osganian SK, Cox GF, Towbin JA, Colan SD, Lurie PR, Sleeper LA, Orav EJ, **Lipshultz SE**. Design and implementation of a north american pediatric cardiomyopathy registry. *Am Heart J* 139:S86-S95 (2000). PMID: 10650321
69. Saidi A, Moodie D, Garson A, **Lipshultz SE**, Kaplan S, Lai W, Colan S, Starc T, Shanbhag S, Easley K, Bricker T, The P²C² HIV Study Group. Electrocardiography and 24-hour electrocardiographic ambulatory recording (Holter Monitor) studies in children of mothers infected with human immunodeficiency virus type 1. *Pediatr Cardiol* 21(3):189-196 (2000). PMID: 10818172
70. **Lipshultz SE**, Easley KA, Orav EJ, Kaplan S, Starc TJ, Bricker JT, Lai WW, Moodie DS, Sopko G, McIntosh K, Colan SD. Absence of cardiac toxicity of zidovudine in infants. *N Engl J Med* 343:759-766 (2000). PMID: 10984563
71. Demmler GJ, Iastas A, Easley KA, Kovacs A, for **the P²C² HIV Study Group**. Results of a quality assurance program for detection of cytomegalovirus infection in the pediatric pulmonary

- and cardiovascular complications of vertically transmitted human immunodeficiency virus (P²C² HIV) infection study. *J Clin Microbiology* 38:3942-3945 (2000). PMID: 11060049
72. Shearer WT, Easley KA, Goldfarb J, Rosenblatt HM, Jenson HB, Kovacs A, McIntosh K, **for the P²C² HIV Study Group**. Prospective five-year study of peripheral blood CD4+, CD8+, and CD19+/CD20+ lymphocytes and serum immunoglobulins in children born to HIV-1 infected women. *J Allergy Clin Immunol* 106:559-566 (2000). PMID: 10984378
 73. Cohen H, Chen XC, Sunkle S, Davis L, Geromanos K, Xanthos G, Shearer W, **The P²C² HIV Study Group**. Ability of caregivers to read delayed hypersensitivity skin tests in children exposed to and infected by HIV. *Journal of Pediatric Health Care* 14:50-55 (2000). PMID: 10736138
 74. Shearer WT, Easley KA, Goldfarb J, Jenson HB, Rosenblatt HM, Jenson HB, Kovacs A, McIntosh K, **for the P²C² HIV Study Group**. Evaluation of immune survival factors in pediatric HIV-1 infection. *Ann NY Acad Sci* 918:298-312 (2000). PMID: 11144332
 75. Grenier MA, Fioravanti J, Truesdell SC, Mendelsohn AM, Vermilion RP, **Lipshultz SE**. Angiotensin-converting enzyme inhibitor therapy for ventricular dysfunction in infants, children and adolescents: A review. *Prog Ped Cardiol* 12(1):91-111 (2000). PMID: 11114549
 76. **Lipshultz SE**. Ventricular dysfunction clinical research in infants, children and adolescents. *Prog Ped Cardiol*. 12(1):1-28 (2000). PMID: 11114543
 77. Kattan M, Platzker A, Mellins RB, Schluchter MD, Chen XC, Peavy H, Steinbach S, Wohl ME, Hiatt P, Hunter J, Colin AA, **The P²C² HIV Study Group**. Respiratory diseases in the first year of life in children born to HIV-1-infected women. *Pediatric Pulmonology* 31:267-276 (2001). PMID: 11288208
 78. Lipsitz SR, Leong T, Ibrahim J, **Lipshultz SE**. A partial correlation coefficient and coefficient of determination for multivariate normal repeated measures data. *J Royal Statistical Society Series D (The Statistician)* 50:87-95 (2001).
 79. Colin AA, Rao JS, Chen XC, Hunter JM, Hanrahan J, Hiatt P, Kattan M, Koumbourlis A, Mellins RB, Peavy HH, Platzker A, Ting A, Steinbach S, Wohl ME, **The P²C² HIV Study Group**. Forced expiratory flow in uninfected infants and young children born to HIV-infected mothers. *Amer J Respir Crit Care Med* 163:865-873 (2001). PMID: 11282758
 80. Norton KI, Kattan M, Rao JS, Cleveland R, Trautwein L, Mellins RB, Berdon W, Boechat MI, Wood B, Meziame M, Platzker ACG, **The P²C² Study Group**. Chronic radiographic lung changes in children with vertically transmitted HIV-1-infection. *Am J Roentgenology* 176:1553-1558 (2001). PMID: 11373231
 81. Langston C, Cooper ER, Goldfarb J, Easley KA, Husak S, Sunkle S, Starc TJ, Colin AA, **The P²C² Study Group**. Human immunodeficiency virus-related mortality in infants and children: Data from the Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV (P²C²) study. *Pediatrics* 107:328-338 (2001). PMID: 11158466
 82. **Lipshultz SE**, Easley K, Orav EJ, Lai W, Starc T, Bricker JT, Ayres N, Kaplan S, Moodie D, Schluchter M, Sopko G, Colan SD, **for the P²C² study group**. The reliability of multicenter pediatric echocardiographic measurements of left ventricular structure and function. *Circulation* 104:310-316 (2001). PMID: 11457750
 83. Lai WW, Colan SD, Easley KA, **Lipshultz SE**, Starc TJ, Bricker JT, Kaplan S, **for the P²C² Study Group**. Dilatation of the aortic root in children infected with human immunodeficiency virus type I: The prospective P²C² HIV multicenter study. *Am Heart J* 141:661-70 (2001). PMID: 11275935
 84. Meyers A, Shah A, Cleveland RH, Cranley WR, Wood B, Sunkle S, Husak S, Cooper ER, **for the P²C² HIV Study Group**. Thymic size on chest radiograph and rapid disease progression in

- human immunodeficiency virus 1-infected children. *Pediatr Infect Dis J* 20:1112-8 (2001). PMID: 11740315
85. Miller TL, Easley KA, Zhang W, Orav EJ, Bier DM, Luder E, Ting A, Shearer WT, Vargas JH, **Lipshultz SE**, for the P²C² HIV Study Group. Maternal and infant factors associated with failure to thrive in children with vertically-infected HIV-1 infection: The prospective, P²C² HIV multicenter study. *Pediatrics* 108:1287-96 (2001). PMID: 11731650
 86. Herman EH, Zhang J, Rifai N, **Lipshultz SE**, Hasinoff BB, Chadwick DP, Knapton A, Chai J, Ferrans VJ. The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity. *Cancer Chemother Pharmacol* 48:297-304 (2001). PMID: 11710630
 87. Fisher S, **Lipshultz SE**. Epidemiology of cardiovascular involvement in HIV disease and AIDS. *Ann NY Acad Sci*. 946:13-22 (2001). PMID: 11762981
 88. Keesler M, Fisher S, **Lipshultz SE**. Cardiovascular manifestations of pediatric HIV infection: Results of the P²C² HIV study. *Ann NY Acad Sci*. 946:169-178 (2001). PMID: 11762985
 89. **Lipshultz SE**, Fisher SD, Lai W, Miller TL. Cardiac monitoring and therapy for HIV-infected patients. *Ann NY Acad Sci*. 946:236-273 (2001). PMID: 11762991
 90. **Lipshultz SE**. Absence of cardiac toxicity of zidovudine in infants (letter). *N Engl J Med* 344:458 (2001). PMID: 11221608
 91. Simbre VC II, Adams MJ, Deshpande SS, Duffy SA, Miller TL, **Lipshultz SE**. Cardiomyopathy caused by antineoplastic therapies. *Current Treatment Options in Cardiovascular Medicine* 3:493-506 (2001). PMID: 11696269
 92. Barbaro G, Fisher SD, Giancaspro G, **Lipshultz SE**. HIV-associated cardiovascular complications: a new challenge for emergency physicians. *Am J Emerg Med*. 19:566-574 (2001). PMID: 11699002
 93. Chinen J, Easley KA, Mendez H, Shearer WT, for the P²C² HIV Study Group. Decline of CD3 T-cell counts by six months of age is associated with rapid disease progression in HIV-1-infected infants. *J Allergy Clin Immunol* 108:266-268 (2001). PMID: 11496244
 94. Barbaro G, Fisher SD, **Lipshultz SE**. Pathogenesis of HIV-associated cardiovascular complications. *The Lancet Infectious Diseases*. 1:115-124 (2001). PMID: 11871462
 95. Barbaro G, **Lipshultz SE**. Pathogenesis of HIV-associated cardiomyopathy. *Ann NY Acad Sci* 946:57-82 (2001). PMID: 11762996
 96. Barbaro G, Fisher SD, Pellicelli AM, **Lipshultz SE**. The expanded role of the cardiologist in the care of HIV infected patients. *Heart* 86:365-67 (2001). PMID: 11559669
 97. Starc TJ, **Lipshultz SE**, Easley KA, Kaplan S, Bricker JT, Colan SD, Lai WW, Gersony WM, Sopko G, Moodie DS, Schluchter MD. Incidence of cardiac abnormalities in children with human immunodeficiency virus infection: The prospective P²C² HIV study. *J Pediatr* 141(3):327-34 (2002). PMID: 12219051
 98. Jenson HB, Gauntt CJ, Easley KA, Pitt J, **Lipshultz SE**, McIntosh K, Shearer WT for the P²C² Study Group. Evaluation of coxsackievirus infection in children with Human Immunodeficiency Virus type 1-associated cardiomyopathy. *J Infect Dis* 185:1798-802 (2002). PMID: 12085328
 99. **Lipshultz SE**, Easley KA, Orav EJ, Kaplan S, Starc TJ, Bricker JT, Lai WW, Moodie DS, Sopko G, Schluchter MD, Colan SD, The P²C² HIV Study Group. Cardiovascular status of infants and children of women infected with HIV-1 (P²C² HIV): a cohort study. *The Lancet* 360:368-73 (2002). PMID: 12241776
- Featured by an editorial commentary by Ensing G. "Cardiac complications with vertically transmitted HIV infection" *Lancet* 2002;360(9330):350-351 and also by a press release by The Lancet.

100. **Lipshultz SE**, Lipsitz SR, Sallan SE, Simbre VC II, Shaikh SL, Mone SM, Gelber RD, Colan SD. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. *J Clin Oncol* 20:4517-22 (2002). PMID: 12454107
101. **Lipshultz SE**, Giantris AL, Lipsitz SR, Kimball Dalton V, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Gelber RD, Sallan, Colan SD. Continuous doxorubicin infusion is not cardioprotective: The Dana Farber 91-01 ALL protocol. *J Clin Oncol* 20:1677-1682 (2002). PMID: 11896119
102. Lipsitz SR, Fitzmaurice GM, Ibrahim JG, Gelber R, **Lipshultz S**. Parameter estimation in longitudinal studies with outcome-dependent follow-up. *Biometrics* 58(3):621-30 (2002). PMID: 12229997
103. Parzen M, Lipsitz SR, Ibrahim JG, **Lipshultz S**. A weighted estimating equation for linear regression with missing covariate data. *Statistics in Medicine* 21(16):2421-36 (2002). PMID: 12210626
104. Grundy SM, Howard B, Smith S, Jr, Eckel R, Redberg R, Bonow RO. (**Lipshultz SE** is listed in the Appendix to the Executive Summary as a member of the Writing Groups who contributed to the content of the Executive Summary published as a correction in *Circulation* 2002;106:282) Prevention Conference VI: diabetes and cardiovascular disease: Executive Summary: Conference proceeding for healthcare professionals from a special writing group of the American Heart Association. *Circulation* 105:2231-2239 (2002). DOI: 10.1161/01.CIR.0000013952.86046.DD. <http://circ.ahajournals.org/cgi/content/full/105/18/2231> and erratum at <http://circ.ahajournals.org/cgi/content/full/circulationaha;106/2/282>. PMID: 11994261
105. Bonow RO, Mitch WE, Nesto RW, O'Gara PT, Becker RC, Clark LT, Hunt S, Jialal I, **Lipshultz SE**, Loh E. Prevention Conference VI. Diabetes and cardiovascular disease. Writing group V: Management of cardiovascular-renal complications. *Circulation* 105:e159-e164 (2002). PMID: 11994267
106. LeClerc JM, Billett AL, Gelber RD, Dalton V, Tarbell N, Lipton JM, Barr R, Clavell LA, Asselin B, Hurwitz C, Schorin M, **Lipshultz SE**, Declerck L, Silverman LB, Cohen HJ, Sallan SE. Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Farber ALL consortium protocol 87-01. *J Clin Oncol* 20:237-46 (2002). PMID: 11773175
107. Simbre VC II, Deshpande SS, Duffy SA, **Lipshultz SE**. Cardiac damage caused by anthracycline therapy in childhood cancer. *Adis New Management in Anthracycline-induced Cardiotoxicity Symposia Proceedings. Part I: Efficacy and cardiotoxicity of anthracyclines in adults and children. Pages 10-14* (2002).
108. Harmon WG, Dadlani GH, Fisher SD, **Lipshultz SE**. Myocardial and pericardial disease in HIV. *Current Treatment Options in Cardiovascular Medicine* 4:497-504 (2002). PMID: 12408791
109. Hinkle AS, Proukou CB, Deshpande SS, Duffy SA, Kozlowski AM, French CA, **Lipshultz SE**. Cardiac late effects and prevention strategies for children treated with anthracyclines. *Touch Cardiology – Independent insight for medical specialists.* (<http://www.touchcardiology.com/cardiac-late-effects-prevention-a407-1.html>) (Accessed 11/23/07) (2002).
110. **Lipshultz SE**, Sleeper LA, Towbin JA, Lowe AM, Orav EJ, Cox GF, Lurie PR, McCoy KL, McDonald MA, Messere JE, Colan SD. The incidence of pediatric cardiomyopathy in two regions of the United States. *N Engl J Med* 348:1647-55 (2003). PMID: 12711739
 - Featured with an editorial

111. Al-Attar I, Orav EJ, Exil V, Vlach SA, **Lipshultz SE**. Predictors of cardiac morbidity and related mortality in children with acquired immunodeficiency syndrome. *J Am Coll Cardiol* 41:1598-605 (2003). PMID: 1274230
112. **Lipshultz SE**, Somers MJ, Lipsitz SR, Colan SD, Jabs K, Rifai N. Serum cardiac troponin and subclinical cardiac status in pediatric chronic renal failure. *Pediatrics* 112:79-86 (2003). PMID: 12837871
113. Benun J, Fisher SD, Orav EJ, Schwartz ML, Exil V, Messere C, **Lipshultz SE**. Cardiac management by pediatricians versus pediatric cardiologists in an inpatient academic center. *Am Heart J* 145:424-9 (2003). PMID: 12660664
114. Fisher SD, Bowles NE, Towbin JA, **Lipshultz SE**. Mediators in HIV-associated cardiovascular disease: a focus on cytokines and genes. *AIDS* 17:S29-35 (2003). PMID: 12870528
115. Rivenes SM, Colan SD, Easley KA, Kaplan S, Jenkins KJ, Khan MN, Lai WW, **Lipshultz SE**, Moodie DS, Starc TJ, Sopko G, Zhang W, Bricker JT, for the P²C² HIV study group. Usefulness of the pediatric electrocardiogram in detecting left ventricular hypertrophy: Results from the Prospective Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection (P²C² HIV) Multicenter study. *Am Heart J* 145:716-23 (2003). PMID: 12679770
116. **Lipshultz SE**, Fisher SD, Lai WW, Miller TL. Cardiac risk factors, monitoring and therapy for HIV-infected patients. *AIDS* 17 (suppl 1):S96-S122 (2003). PMID: 12870537
117. Adams MJ, **Lipshultz SE**, Schwartz C, Fajardo LF, Coen V, Constine LS. Radiation-associated cardiovascular disease: manifestations and management. *Semin Radiat Oncol* 13:346-56 (2003). PMID: 12903022
118. Dadlani GH, Harmon WG, Simbre VC II, Tisma-Dupanovic S, **Lipshultz SE**. Cardiomyocyte injury to transplant: pediatric management. *Curr Opin Cardiol* 18(2):91-7 (2003). PMID: 12652211
119. Adams MJ, Hardenbergh PH, Constine LS, **Lipshultz SE**. Radiation-associated cardiovascular disease. *Crit Rev Oncol Hematol* 45:55-75 (2003). PMID: 12482572
120. Kearney DL, Perez-Atayde AR, Easley KA, Bowles NE, Bricker JT, Colan SD, Kaplan S, Lai WW, **Lipshultz SE**, Moodie DS, Sopko G, Starc TJ, Towbin JA for the Pediatric Pulmonary and Cardiovascular complications of Vertically Transmitted HIV infection (P²C² HIV) Study Group, National Heart, Lung and Blood Institutes. Postmortem cardiomegaly and echocardiographic measurements of left ventricular size and function in children infected with the human immunodeficiency virus. The Prospective P²C² HIV Multicenter Study. *Cardiovasc Pathol* 12:140-8 (2003). PMID: 12763553
121. Constine LS, Hinkle AS, French CA, Kozlowski AM, Proukou C, Lipsitz SR, Miller TL, Vermilion RP, Rifai N, **Lipshultz SE**. Radiation-associated risk factors for premature cardiovascular disease in childhood cancer survivors include accelerated atherosclerosis. *Int J Radiat Oncol Biol Phys*. 57(2 Suppl):S199-S200 (2003).
122. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F. (**Dr. Lipshultz** named in the appendix as a member of the working and groups). AHA/CDC Scientific Statement. Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. *Circulation* 107:499-511 (2003). PMID: 12551878
123. **Lipshultz SE**, Lipsitz SR, Sallan SE, Gelber RD, Colan SD. Treatment for asymptomatic anthracycline-induced cardiac dysfunction in childhood cancer survivors: the need for evidence. (letter) *J Clin Oncol* 21:3377-8 (2003). PMID: 12947081

124. Zareba KM, **Lipshultz SE**. Cardiovascular complications in patients with HIV infection. *Curr Infect Dis Rep* 5:513-520 (2003). PMID: 14642194
125. **Lipshultz SE**, Vermilion RP, Alfieris G. Introduction to optimal delivery of care for pediatric cardiovascular disease. *Prog Pediatr Cardiol* 18:1 (2003).
126. RTI International (**Lipshultz SE** – a named participating partner). A public health action plan for advancing cancer survivorship. RTI International Project # 08633.002. A publication of the US Centers for Disease Control and Prevention. (Oct 2003). Pages 1-42.
127. HIV Paediatric Prognostic Markers Collaborative Study Group including the **P²C² HIV Study Group**. Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. *Lancet* 362:1605-11 (2003). PMID: 14630440
128. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. (**Dr. Lipshultz** is listed on page 178 in Table 2 as a member of the Heart Late Effects Workshop CTC Committee whose work was featured in this paper). *Semin Rad Oncol* 13(3):176-181 (2003). PMID: 12903007
129. Swain SM, Vici P, **for the expert panel**. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. *J Cancer Res Clin Oncol*. 130(1):1-7. Epub 2003 Oct 17. (2004). PMID: 14564513
130. Nanavati KA, Fisher SD, Miller TL, **Lipshultz SE**. HIV-related cardiovascular disease and drug interactions. *Amer J Cardiovasc Drugs* 4:315-24 (2004). PMID: 15449973
131. Mone SM, Gillman MW, Miller TL, Herman EH, **Lipshultz SE**. Effects of environmental exposures on the cardiovascular system: prenatal period through adolescence. *Pediatrics* 113(4 Suppl):1058-69 (2004). PMID: 15060200
132. Geromanos K, Sunkle SN, Mauer MB, Carp D, Ancker J, Zhang W, Easley KA, Schluchter MD, Kozinetz CA, Mellins RB, **for the P²C² Study Group**. Successful techniques for retaining a cohort of infants and children born to HIV-infected women: the prospective P²C² HIV study. *J Assoc Nurses AIDS Care* 15:48-57 (2004). PMID: 15296658
133. **Lipshultz SE**, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, Colan SD, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Gelber RD, Sallan SE. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. *N Engl J Med* 351:145-53 (2004). PMID: 15247354
134. Hinkle AS, Proukou C, French CA, Kozlowski AM, Constine LS, Lipsitz SR, Miller TL, **Lipshultz SE**. A clinic-based, comprehensive care model for studying late effects in long-term survivors of pediatric illnesses. *Pediatrics* 113(4 Suppl):1141-5 (2004). PMID: 15060211
135. Gillman MW, Rich-Edwards JW, Rifas-Shiman SL, Lieberman ES, Kleinman KP, **Lipshultz SE**. Maternal age and other predictors of newborn blood pressure. *J Pediatr* 144:240-245 (2004). PMID: 14760269
136. Gillman MW, Rifas-Shiman SL, Kleinman KP, Rich-Edwards JW, **Lipshultz SE**. Maternal calcium intake and offspring blood pressure. *Circulation* 110:1990-5 (2004). PMID: 15451777
137. Lavigne JE, Shearer WT, Thompson B, Orav EJ, Starc TJ, Colan SD, Pignatelli R, O'Brien SE, Bezold L, LaRusa P, Easley KA, Cheng I, Duffy SA, **Lipshultz SE** for the CHAART Study Group. Cardiovascular outcomes of pediatric seroreverters perinatally exposed to HAART: Design of a longitudinal clinical study. *Cardiovasc Toxicol* 4:187-98 (2004). PMID: 15371634
138. Zareba KM, Lavigne JE, **Lipshultz SE**. Cardiovascular effects of HAART in infants and children of HIV-infected mothers. *Cardiovasc Toxicol* 4:271-80 (2004). PMID: 15470274

139. Adams MJ, Lipsitz SR, Colan SD, Tarbell NJ, Treves ST, Diller L, Greenbaum N, Mauch P, **Lipshultz SE**. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. *J Clin Oncol* 22:3139-48 (2004). PMID: 15284266
140. **Lipshultz SE**, Colan SD. Cardiovascular trials in long-term survivors of childhood cancer (commentary). *J Clin Oncol* 22(5):769-773 (2004). PMID: 14990630
141. Tsirka AE, Trinkaus K, Chen SC, **Lipshultz SE**, Towbin JA, Colan SD, Exil V, Strauss AW, Canter CE. Improved outcomes of pediatric dilated cardiomyopathy with utilization of cardiac transplantation. *J Am Coll Cardiol* 44:391-7 (2004). PMID: 15261937
142. George R, **Lipshultz SE**, Lipsitz SR, Colan SD, Diller L. Association between congenital cardiovascular malformations and neuroblastoma. *J Pediatr* 144:444-448 (2004). PMID: 15069390
- Featured with an editorial.
143. **Lipshultz SE**. Children first. *University of Miami Medicine* 6(2):6-7 (2004).
144. Koumbourlis AC, Chen XC, Rao JS, Schluchter MD, Easley K, Colin AA, Hiatt P, Kattan M, McCarthy K, Mellins RB, Peavy H, Platzker AC, Steinbach S, Ting A, Weisner MD, Wohl ME **for the P²C² HIV Study Group**. Maximal expiratory flow at FRC (V[']maxFRC): Methods of selection and differences in reported values.in partial expiratory flow volume (PEFV) curves. *Pediatr Pulmonol* 37(4):318-23 (2004). PMID: 15022128
145. Constine LS, **Lipshultz SE**. Heart of the matter: Risk factors for premature cardiovascular disease in cancer survivors. *American Society of Clinical Oncology Educational Book 40th Annual Meeting*. Spring 2004. Editor: Perry MC. Pages 418-424.
146. **Lipshultz SE**, Silverman LB, Sallan SE. Doxorubicin-induced myocardial injury (letter). *N Engl J Med* 351:1908-9 (2004). PMID: 15509827
147. **Lipshultz SE**. From the Department Chairmen. *FL Pediatrician*. 27:7,26 (2004).
148. Flynn JT, Newberger JW, Daniels SR, Sanders SP, Portman RJ, Hogg RJ, Saul JP for the **PATH-1 Investigators**. A randomized, placebo-controlled trial of amlodipine in children with hypertension. *J Pediatr* 145:353-9 (2004). PMID: 15343191
149. Perez-Atayde AR, Kearney DL, Bricker JT, Colan DS, Easley KA, Kaplan S, Lai WW, **Lipshultz SE**, Moodie DS, Sopko G, Stare TJ, for the P²C² HIV Study. Cardiac, aortic, and pulmonary arteriopathy in HIV-infected children: the prospective P²C² HIV multicenter study. *Pediatr Dev Pathol Mar* 17;7(1) [Epub ahead of print] and 7:61-70 [print version] (2004). PMID: 15255036
150. Smith SC, Jr., Anderson JL, Cannon RO III, Fadl YY, Koenig W, Libby P, **Lipshultz SE**, Mensah GA, Ridker PM, Rosenson R. CDC/AHA workshop on markers of inflammation and cardiovascular disease: Application to clinical and public health practice. Report from the clinical practice discussion group. *Circulation* 110:e550-e553 (2004). DOI:10.1161/01/CIR.0000148981.71644.C7. <http://circ.ahajournals.org/cgi/content/full/110/25/e550>. PMID: 15611380
151. **Lipshultz SE**. From the Department Chairmen: Update from the Department of Pediatrics at the University of Miami. *FL Pediatrician* 28(2):11, 30, 31 (2005).
152. Huh SY, Rifas-Shiman SL, Kleinman KP, Rich-Edwards JW, **Lipshultz SE**, Gillman MW. Maternal protein intake is not associated with infant blood pressure. *Int J Epidemiol* 34(2):378-384 (2005). Dec 2, 2004 epub ahead of print. PMID: 15576466
153. Lipinczyk TM, **Lipshultz SE**. Cardioprotective effects of dexrazoxane in children with acute lymphoblastic leukemia treated with doxorubicin: An overview. *Am J Oncol Rev* 4(2):103-116 (2005).
154. Simbre VC II, Duffy SA, Dadlani GH, Miller TL, **Lipshultz SE**. Cardiotoxicity of cancer chemotherapy: Implications for children. *Pediatr Drugs* 7(3):187-202 (2005). PMID: 15977964

155. Zareba KM, Miller TL, **Lipshultz SE**. Cardiovascular disease and toxicities related to HIV infection and its therapies. *Expert Opin Drug Saf* 4(6):1017-25 (2005). PMID: 16255661
156. Dadlani GH, Gingell RL, Orié JD, Roland JM, Najdzionek J, Lipsitz SR, Pieroni DR, **Lipshultz SE**. Coronary artery calcifications in the long-term follow-up of Kawasaki disease. *Am Heart J* 150(5):1016.e1-1016.e8 (2005). PMID: 16290989
157. **Lipshultz SE**, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD, Colan SD. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. *J Clin Oncol* 23:2629-2636 (2005). PMID: 15837978
158. **Lipshultz SE**, Vlach SA, Lipsitz SR, Sallan SE, Schwartz ML, Colan SD. Cardiac changes associated with growth hormone therapy in children treated with anthracyclines. *Pediatrics* 115(6):113-22 (2005). PMID: 15930224
159. Miller TL, Horgan S, **Lipshultz SE**. Exercise rehabilitation of pediatric patients with cardiovascular disease. *Prog Pediatr Cardiol* 20(1):27-37 (2005).
160. Alfieris GM, Dadlani GH, Vermilion RP, Smith FC, Atallah-Yunes NH, Dawson CE, Cable RC, Orav EJ, Kozlowski A, Gaum WE, **Lipshultz SE**. Regional sharing optimizes arterial switch outcomes. *Prog Pediatr Cardiol* 20:21-25 (2005). Corrigendum appears in *Prog Pediatr Cardiol* 20:207 (2005).
161. Fisher SD, Easley KA, Orav EJ, Colan SD, Kaplan S, Starc TJ, Bricker JT, Lai WW, Moodie DS, Sopko G, **Lipshultz SE**. Mild dilated cardiomyopathy and increased left ventricular mass predict mortality: The prospective P²C² HIV Multicenter study. *Am Heart J* 150(3):439-47 (2005). PMID: 16169321
162. George R, **Lipshultz SE**, Colan SD, Lipsitz SR, Diller L. Neural crest mediated cardiac development. *J Pediatr* 146(3):441-3 (2005). PMID: 15756248
163. Wouters KA, Kremer LC, Miller TL, Herman EH, **Lipshultz SE**. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. *Br J Haematol*. Published online in advance of print edition on September 29, 2005 (doi :10.1111/j.1365-2141.2005.05759.x). Print citation: 131(5):561-78 (2005). PMID: 16351632
164. Adams MJ, Mauch P, Colan SD, Tarbell NJ, Diller L, Treves ST, **Lipshultz SE**. Cardiac toxicity of mediastinal radiotherapy: Which are the critical structures? *J Clin Oncol* 23:3636 (2005). PMID: 15908679
165. Tsirka AE, Trinkaus K, Chen SC, **Lipshultz SE**, Towbin JA, Colan SD, Exil V, Strauss AW, Canter CE. Pediatric dilated cardiomyopathy – current issues. *J Am Coll Cardiol* 45(10):1734 (2005). PMID: 15893200
166. Adams MJ, **Lipshultz SE**. Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: Implications for screening and prevention. *Pediatr Blood Cancer* 44(7):600-606 (2005). PMID: 15856486
167. **Lipshultz SE**. Realizing optimal care for children with cardiovascular disease: Funding challenges and research approaches. *Prog Pediatr Cardiol* 20:71-90 (2005).
168. Sallan SE, **Lipshultz SE**. Wise up: Do not do it without protection! *Pediatr Blood Cancer* 45:72-873 (Oct 3; Epub ahead of print – Wiley InterScience, DOI 10.1002/pbc.20568) (2005). PMID: 16206201
169. **Lipshultz SE** and Miller TL. Establishing norms for echocardiographic measurements of cardiovascular structures and function in children. *J Appl Physiol* 99(2):386-8 (2005). PMID: 16020433
170. Hale ER, **Lipshultz SE**, Constine LS. Latent cardiac injury following the double-edged sword of chemotherapy and radiation. *American Society of Clinical Oncology 2005 Educational Book*

- (ISSN 1548-8748) Alexandria, VA: American Society of Clinical Oncology (Editor: Perry MC). Pages 739-746 (2005).
171. Sweeney HL, Cripe L, Dubin AM, Furlong P, **Lipshultz SE**, McCurdy K, McNally E, Perez-Atayde A, Seidman C, Silberbach GM, Strauss A, Towbin J, Fakunding J. Executive Summary: NHLBI Working Group on Cardiomyopathies in children with rare diseases. (Dr. Lipshultz is cited as a member of the working group). (2005)
<http://www.nhlbi.nih.gov/meetings/workshops/cardiomyopathies.htm>.
 172. Fisher SD, Miller TL, **Lipshultz SE**. Impact of HIV and highly active antiretroviral therapy on leukocyte adhesion molecules, arterial inflammation, dyslipidemia, and atherosclerosis. *Atherosclerosis* Nov 14: [Epub ahead of print] (doi 10.1016/j.atherosclerosis.2005.09.025, ATH-D-05-00292) (2005). March 2006; 185 (1): 1-11. PMID: 16297390
 173. **Lipshultz SE**, Wong J, Lipsitz SR, Zareba KM, Rifai N. Frequency of clinically unsuspected myocardial injury at a children's hospital. *Am Heart J* 151:916-22 (2006). PMID: 16569563
 174. Towbin JA, Sleeper LA, Lowe AM, Orav EJ, Clunie S, Messere J, Colan SD, Cox GF, Lurie P, **Lipshultz SE**. Etiology, incidence, and outcome of dilated cardiomyopathy in children: The pediatric cardiomyopathy registry experience. *J Am Med Assoc* 296(15):1867-76 (2006). PMID: 17047217
 175. Cox GF, Sleeper LA, Lowe AM, Towbin JA, Colan SD, Orav EJ, Lurie P, Messere JE, **Lipshultz SE**. Factors associated with establishing a causal diagnosis for children with cardiomyopathy. *Pediatrics* 118(4):1519-1531 (2006). PMID: 17015543
 176. George RE, **Lipshultz SE**, Lipsitz SR, Colan SD, Diller L. Congenital cardiovascular malformations are complicated in neuroblastoma identified by mass screening but not by clinical examination in Japan (letter). *J Pediatr* 149:145-6 (2006). PMID: 16860148
 177. **Lipshultz SE**. Exposure to anthracyclines during childhood causes cardiac injury. *Semin Oncol* 33(3 Suppl 8):8-14 (2006). PMID: 16781284
 178. Adams MJ, Hinkle AS, Constine LS, **Lipshultz SE**. Anthracycline cardiotoxicity in a childhood cancer survivor: A case report and review (Featured Case Study). *J Clin Oncol Rev* 5(1):31-8 (2006).
 179. Fitzmaurice GM, Lipsitz SR, Ibrahim JG, Gelber R, **Lipshultz S**. Estimation in regression models for longitudinal binary data with outcome-dependent follow-up. *Biostatistics*. 2006 Jan 20; [Epub ahead of print]. 7(3):469-485 (2006). PMID: 16428260
 180. **Lipshultz SE**. Introduction - Anthracycline-induced cardiotoxicity in cancer patients: the scope of the problem. *Semin Oncol* 33(3Suppl 8):1 (2006). PMID: 16781284
 181. Herman E, Zhang J, Knapton A, **Lipshultz SE**, Rifai N, Sistare F. Serum cardiac troponin T as a biomarker for acute myocardial injury induced by low doses of isoproterenol in rats. *Cardiovasc Toxicol* 6(3-4):211-22 (2006). PMID: 17347531
 182. **Lipshultz SE**, Cohen H, Colan SD, Herman EH. The relevance of information generated by in vitro experimental models to clinical doxorubicin cardiotoxicity (commentary). *Leuk Lymphoma* 47(8):1454-8 (2006). PMID: 16966253
 183. **Lipshultz SE**, Fisher SD, Miller TL, Sharma TS, Milton AN. The cardiovascular manifestations of HIV infection. *Dialogues Cardiovasc Med* 12(1):5-23 (2007).
• This issue was dedicated to Dr. Lipshultz' team and its work in this area. This was the featured article. There was an Invited Editorial as well. It was: Boon NA. HIV and the heart. *Dialogues Cardiovasc Med* 2007;12(1):3-4. (http://www.dialogues-cvm.org/pdf/43/DCVM43_01.pdf).
 184. **Lipshultz SE**, Alvarez JA, Wilkinson JD. HIV & cardiovascular disease: Summaries of ten seminal papers. *Dialogues Cardiovasc Med* 12:61-71 (2007).

185. Colan SD, **Lipshultz SE**, Lowe AM, Sleeper LA, Messere J, Cox GF, Lurie PR, Orav EJ, Towbin JA. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: Findings from the pediatric cardiomyopathy registry. *Circulation* 115(6):773-81. Jan 29; [Epub ahead of print, doi:10.1161/CIRCULATIONAHA.106.621185, pages 1-9] (2007). An online-only Data Supplement, consisting of tables, is available with this article at <http://circ.ahajournals.org/cgi/content/full/CIRCULATIONAHA.106.621185/DC1>. An accompanying "Clinical Perspective" accompanies this article. PMID: 17261650
186. Alvarez JA, Scully RE, Miller TL, Armstrong FD, Constine LS, Friedman DL, **Lipshultz SE**. Long-term effects of treatments for childhood cancer. *Curr Opin Pediatr*. 19(1):23-31 (2007). PMID: 17224658
187. Barry E, Alvarez JA, Scully RE, Miller TL, **Lipshultz SE**. Anthracycline-induced cardiotoxicity: Pathophysiology, course, prevention, and management. *Expert Opin Pharmacother* 8(8):1039-58 (2007). PMID: 17516870
188. Moghrabi A, Levy DE, Asselin B, Barr R, Clavell L, Hurwitz C, Samson Y, Schorin M, Dalton VK, **Lipshultz SE**, Neuberger DS, Gelber RD, Cohen HJ, Sallan SE, Silverman LB. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. *Blood* (Epub ahead of print – Sept 26, 2006) 109(3):896-904 (2007). PMID: 17003366
189. **Lipshultz SE**. Heart failure in childhood cancer survivors. *Nat Clin Pract Oncol* 2007 4(6):334-5. Apr 24; [Epub ahead of print], (2007). Correction due to error in the section written by the editor in *Nat Clin Pract Oncol*. 2007 Nov;4(11):669, PMID: 17965645. PMID: 17457311
190. Adams MJ, Constine LS, **Lipshultz SE**. Late effects of therapy for Hodgkin's lymphoma. *Current Hematologic Malignancy Reports*. 2(3):143-150 (2007).
191. Constine LS, **Lipshultz SE**. How cytotoxic therapy for Hodgkin's Lymphoma can break your heart. *American Society of Clinical Oncology 2007 Educational Book* (ISSN 1548-8748) Alexandria, VA: American Society of Clinical Oncology (Editor: Perry MC). Pages 1-7. (accepted article #094 – published) (2007).
192. Scully RE, **Lipshultz SE**. Anthracycline cardiotoxicity in long-term survivors of childhood cancer. *Cardiovasc Toxicol* 7:122-128 (2007). PMID: 17652816
193. Miller TL, Lipsitz SR, Lopez-Mitnik G, Hinkle AS, Constine LS, Adams MJ, French C, Prokou C, Rovitelli A, **Lipshultz SE**. Characteristics and determinants of adiposity in pediatric cancer survivors. *Cancer Epidemiol Biomarkers Prev* 19(8):2013-22. Epub 2010 Jul 20. doi: 10.1158/1055-9965. PMID: 20647396. (2010).
194. **Lipshultz SE**, Colan SD, Towbin JA, Wilkinson JD. Introduction: Idiopathic and Primary Cardiomyopathies in Children. *Prog Pediatr Cardiol* 24:3 (2007).
195. **Lipshultz SE**, Colan SD, Towbin JA, Wilkinson JD. Preface - Idiopathic and primary cardiomyopathies in children. *Prog Pediatr Cardiol* 24:1 (2007).
196. Sokol KC, Armstrong FD, Rosenkranz ER, Hsu D, Schultz SE, Cantwell GP, Ricci M, **Lipshultz SE**. Ethical issues in children with cardiomyopathy: Making sense of ethical challenges in the clinical setting. *Prog Pediatr Cardiol* 23:81-87 (2007).
197. Alvarez JA, Wilkinson JD, **Lipshultz SE**, for the Pediatric Cardiomyopathy Registry Study Group. Outcome predictors for pediatric dilated cardiomyopathy: A systematic review. *Prog Pediatr Cardiol* 23:25-32 (2007). PMID: 19701490
198. Ratnasamy C, Kinnamon DD, **Lipshultz SE**, Rusconi PG. Associations between neurohormonal and inflammatory activation and heart failure in children. *Prog Pediatr Cardiol* 24:81-82 (2007).

199. **Lipshultz SE**, Lipsitz SR, Orav EJ. Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin's disease: a claim without compelling evidence. *J Clin Oncol* 25(21):3179 (2007). PMID: 17634500
200. Natarajan S, Lipsitz S, Parzen M, **Lipshultz S**. A measure of partial association for generalized estimating equations. *Statistical Modelling* 7:175-190 (2007).
201. Ryu D, Sinha D, Mallick B, Lipsitz SR, **Lipshultz SE**. Longitudinal studies with outcome-dependent follow-up: Models and Bayesian regression. *Journal of the American Statistical Association (JASA-Theory and Methods Section)*. 102 (479): 952-967 (2007). PMID: 18392118
202. Lin Y, Lipsitz SR, Sinha D, Fitzmaurice GM, **Lipshultz S**. Bayesian extension of Fisher's exact test in the presence of missing data. *Statistics in Biopharmaceutical Research* (Accepted – In press) (2010).
203. Shearer WT, Pahwa S, Read JS, Chen J, Wijayawardana SR, Palumbo P, Abrams EJ, Nesheim SR, Yin W, Thompson B, Easley KA, **P²C² HIV Investigator Group**. CD4/CD8 T-cell ratio predicts HIV infection in infants: The National Heart, Lung, and Blood Institute P²C² study. *J Allergy Clin Immunol* 2007;120:1449-56. PMID: 17920669
204. Zhang J, Shaw M, Keenan J, Kilty CG, **Lipshultz SE**, Knapton A, Vaidya VS, Bonventre JV, Herman EH. Changes in the renal expression of RPA-1, RPA-2, and KIM-1 in spontaneously hypertensive rats given doxorubicin or mitoxantrone alone or with dexrazoxane pretreatment. *Pharmacol Tox* (submitted, revision completed – under review) (2007).
205. **Lipshultz SE**, Simbre VC 2nd, Hart S, Rifai N, Lipsitz SR, Reubens L, Sinkin RA. Frequency of elevations in markers of cardiomyocyte damage in otherwise healthy newborns. *Am J Cardiol* 102(6):761-6. Epub 2008 Jul 9. (2008). PMID: 18774003
206. **Lipshultz SE**, Alvarez JA, Scully RE. Education in Heart – Clinical Pharmacology: Anthracycline-associated cardiotoxicity in survivors of childhood cancer. *Heart* 94(4):525-533 (doi:10.1136/hrt.2007.136093) (2008). PMID: 18347383
207. Miller TL, Orav EJ, **Lipshultz SE**, Arheart KL, Duggan C, Weinberg GA, Bechard L, Furuta L, Nicchitta J, Gorbach SL, Shevitz A. Risk factors for cardiovascular disease in children infected with Human Immunodeficiency Virus-1. *J Pediatr* 153(4):491-7. [Epub 2008 Jun 9 ahead of print]. (2008). PMID: 18538789
 • Featured with an Editorial (*J Pediatr* 2008;153(4):456-7).
208. Ratnasamy C, Kinnamon DD, **Lipshultz SE**, Rusconi P. Associations between neurohormonal and inflammatory activation and heart failure in children. *Am Heart J* 155(3):527-533 (2008). PMID: 18294492
209. Miller TL, **Lipshultz SE**. Building a pediatric clinical research division. *J Pediatr* 152(1):1-2, 2.e1-2.e2 (2008). This was the featured monthly article in the section entitled “Notes from the Association of Medical School Pediatric Department Chairs, Inc.” PMID: 18154885
210. Hendry JH, Akahoshi M, Wang LS, **Lipshultz SE**, Stewart FA, Trott KR. Radiation-induced cardiovascular injury. *Radiat Environ Biophys* 47(2):189-93. Jan 10 [Epub ahead of print](2008). PMID: 18193445
211. Barry E, Vrooman LM, Dahlberg SE, Neuberg DS, Asselin BL, Athale UH, Clavell LA, Larsen EC, Moghrabi A, Samson Y, Schorin MA, Cohen HJ, **Lipshultz SE**, Sallan SE, Silverman LB. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. *J Clin Oncol* 26(7):1106-11 (2008). PMID: 18309945
212. Connuck DM, Sleeper LA, Colan SD, Towbin JA, Cox GF, Lowe AM, Wilkinson JD, Orav EJ, Cuniberti L, Salbert BA, **Lipshultz SE**. Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: A comparative study from the Pediatric

- Cardiomyopathy Registry. *Am Heart J* 155(6):998-1005. Epub 2008 Mar 19. Available online March 20 2008, DOI : 10.1016/j.ahj.2008.01.018 (2008). PMID: 18513510
213. Miller TL, Grant YT, Neri Almeida D, Sharma T, **Lipshultz SE**. Cardiometabolic disease in Human Immunodeficiency Virus-infected children. *J CardioMetab Syndr* 3(2):98-105 (doi: 10.1111/j.1559-4572.2008.07651.x) (2008). PMID: 18453810
214. Sharma TS, Messiah SE, Fisher SD, Miller TL, **Lipshultz SE**. Accelerated cardiovascular disease and myocardial infarction risk in patients with the Human Immunodeficiency Virus. *J CardioMetab Syndr* 3(2):93-97 (doi: 10.1111/j.1559-4572.2008.07635.x) (2008). PMID: 18453809
215. Zhang J, Knapton A, **Lipshultz SE**, Weaver JL, Herman EH. Isoproterenol-induced cardiotoxicity in Sprague-Dawley rats: Correlation of reversible and irreversible myocardial injury with release of cardiac troponin T and roles of iNOS in myocardial injury. *Toxicol Pathol* 36(2):277-278. Epub ahead of print on March 18, 2008. DOI: 10.1177/0192623307313010. (2008). PMID: 18349426
216. Gianni L, Herman EH, **Lipshultz SE**, Minotti G, Sarvazyan N, Sawyer DB. Anthracycline cardiomyopathy: from bench to bedside. *J Clin Oncol* 26 (22): 3777-3784 (2008) Dr. Lipshultz was the corresponding author on this paper where it is stated that all authors contributed equally and are listed alphabetically. PMID: 18669466
217. Grinspoon SK, Grunfeld C, Kotler DP, Currier JS, Lundgren JE, Dube MP, **Lipshultz SE**, Hsue PY, Squires K, Schambelan M, Wilson PWF, Yarasheski KE, Hadigan CM, Stein JH, Eckel RH. State of the science conference. Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS executive summary. *Circulation* 118:1-18 *Circulation* published online June 19, 2008; DOI: 10.1161/CIRCULATIONAHA.107.189622 (<http://circ.ahajournals.org/presenter.jhtml?identifier=3003999> "chronological list" link [No. 71-0449] [published with an Editorial, Top Ten Things to Know, News Release, and 6 writing group articles] (2008). PMID: 18566320
218. Grinspoon SK, Grunfeld C, Kotler DP, Currier JS, Lundgren JE, Dube MP, **Lipshultz SE**, Hsue PY, Squires K, Schambelan M, Wilson PWF, Yarasheski KE, Hadigan CM, Stein JH, Eckel RH. State of the science conference. Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS executive summary. *JAIDS Published Ahead of Print Post Copyedit*, 20 June 2008 10.1097/01.qai.000325768.ed (2008). PMID: 18566320
219. Dube MP, **Lipshultz SE**, Fichtenbaum CJ, Greenberg R, Schechter AD, Fisher SD and for Working Group 3. Effects of HIV and antiretroviral therapy on the heart and vasculature. *Circulation* 118:1-5 (*Circulation* published online June 19, 2008; DOI: 10.1161/CIRCULATIONAHA.107.189625. (<http://circ.ahajournals.org/presenter.jhtml?identifier=3003999> "chronological list" link [No. 71-0449] [published with an Editorial, Top Ten Things to Know, News Release, Executive Summary, and 6 writing group articles] (2008). PMID: 18566318
220. Dube MP, **Lipshultz SE**, Fichtenbaum CJ, Greenberg R, Schechter AD, Fisher SD and for Working Group 3. Effects of HIV and antiretroviral therapy on the heart and vasculature. *JAIDS Published Ahead of Print Post Copyedit*, 20 June 2008 10.1097/01.qai.0000325771.08047.3d (2008). PMID: 18566318
221. Scully RE, Miller TL, **Lipshultz SE**. Detecting anthracycline-induced cardiotoxicity in survivors of childhood cancer. *American Society of Clinical Oncology 2008 Educational Book* (ISSN 1548-8748) Alexandria, VA: American Society of Clinical Oncology (Editor: Govindan R). Pages 454-458. (2008). (<http://edbook.ascopubs.org/cgi/content/abstract/2008/1/454>)

222. Barry EV, **Lipshultz SE**, Sallan SE. Anthracycline-induced cardiotoxicity: Natural history, risk factors, and prevention. American Society of Clinical Oncology 2008 Educational Book (ISSN 1548-8748) Alexandria, VA: American Society of Clinical Oncology (Editor: Govindan R). Pages 448-453. (2008). (<http://edbookascopubs.org/cgi/content/abstract/2008/1/448>).
223. **Lipshultz SE**, Colan SD, Towbin JA, Wilkinson JD. Introduction: Idiopathic and Primary Cardiomyopathies in Children. *Prog Pediatr Cardiol* 25(1):1 (Available online 2/20/08 – doi: 10.1016/j.ppedcard.2007.11.002) (2008). PMID: 19343090
224. Wilkinson JD, Sleeper LA, Alvarez JA, Bublik N, **Lipshultz SE** for the Pediatric Cardiomyopathy Study Group. The pediatric cardiomyopathy registry: 1995-2007. *Prog Pediatr Cardiol* 25(1):31-36 (Available online 3/5/08 – doi: 10.1016/j.ppedcard.2007.11.006) (2008). PMID: 19343086
225. Wilkinson JD, **Lipshultz SE**. Epidemiological and outcomes research in children with pediatric cardiomyopathy: Discussions from the international workshop on primary and idiopathic cardiomyopathies in children. *Prog Pediatr Cardiol* 25(1):23-25 (available online 3/5/08 doi: 10.1016/j.ppedcard.2007.11.003) (2008). PMID: 19343085
226. Bublik N, Alvarez JA, **Lipshultz SE**. Pediatric cardiomyopathy as a chronic disease: A perspective on comprehensive care programs. *Prog Pediatr Cardiol* 25(1):103-111 (available online 3/5/08 doi: 10.1016/j.ppedcard.2007.11.011) (April 2008). PMID: 19122765
227. Messiah SE, Arheart KL, Luke B, **Lipshultz SE**, Miller TL. Relationship between body mass index and metabolic syndrome risk factors among US 8- to 14-year-olds, 1999 to 2002. *J Pediatr* 153(2):215-221, 2008 Apr 17. [Epub ahead of print] (2008). PMID: 18534237
228. Messiah SE, Arheart KL, **Lipshultz SE**, Miller TL. Body mass index, waist circumference, and cardiovascular risk factors in adolescents. *J Pediatr* 153(6):845-850.e1. Epub ahead of print July 31, 2008. (2008). PMID: 18675434
229. Lipsitz SR, Fitzmaurice GM, Ibrahim JG, Sinha D, Parzen M, **Lipshultz S**. Joint generalized estimating equations for multivariate longitudinal binary outcomes with missing data: an application to acquired immune deficiency syndrome data. *Journal of the Royal Statistical Society: Series A (Statistics in Society)*. 172(1): 3-20 (Published online Sept 22, 2008, DOI: 10.1111/j.1467-985X.2008.00564.x) (2009).
230. Harmon WG, Sleeper LA, Cuniberti L, Messere J, Colan SD, Orav EJ, Towbin JA, Wilkinson JD, **Lipshultz SE**. Practice patterns in treating children with dilated cardiomyopathy: Findings from the North American Pediatric Cardiomyopathy Registry. *Am J Cardiol* 104(2):281-6. Epub 2009 Jun 3. (July 15, 2009 issue). PMID: 19576361
231. Kinnamon DD, Lipsitz SR, Ludwig DA, **Lipshultz SE**, Miller TL. An improved estimator for the hydration of fat-free mass from *in vivo* measurements subject to additive technical errors. *Physiol Meas* 31(4):497-512. [Epub ahead of print Feb 24] (online: <http://stacks.iop.org/0967-3334/31/4/497>) (PMID: 20181998). (2010).
232. Bakker R, Rifas-Shiman SL, Kleinman KP, **Lipshultz SE**, Gillman MW. Maternal calcium intake during pregnancy and blood pressure in the offspring at age 3 years: A follow-up analysis of the Project Viva cohort. *Am J Epidemiol* 168(12):1374-80. [Epub 2008 Oct 22 ahead of print] (2008). PMID: 18945693
233. Schwartz CL, Constine LC, Villaluna D, London WB, Hutchinson RE, Sposto R, **Lipshultz SE**, Turner CS, deAralcon PA, Chauvenet A. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate and high-risk Hodgkin lymphoma: the results of P9425 from the Children's Oncology Group. *Blood*. 114(10):2051-9. 2009 Jul 7. [Epub ahead of print]. *Blood First Edition Paper*, prepublished online July 7, 2009; DOI 10.1182/blood-2008-10-184143. 1. *Blood's First Edition*-prepublication and 2. Print edition of *Blood* (2009). PMID: 19584400

234. Strickman-Stein N, Gervais M-D, Ludwig DA, Messiah SE, **Lipshultz SE**, Miller TL. Body mass index as a function of length of United States residency among Haitian immigrant children. *Ethn Dis* 20(1):22-8 (2010). (PMID: 20178178). Also invited by the Editor-in-Chief to write a patient-friendly summary for concurrent publication in a special "For the Patient" section of the journal.
235. Messiah SE, Arheart KL, **Lipshultz SE**, Miller TL. Ethnic group differences in waist circumference percentiles among U.S. children and adolescents: estimates from the 1999-2008 National Health and Nutrition Examination Surveys. *Metab Syndr Relat Disord* 9(4):297-303. 2011 Apr 5. [Epub ahead of print] (PMID: 21466378) (2011).
236. **Lipshultz SE**, Orav EJ, Towbin JA, Sleeper LA, Messere J, Cuniberti L, Lowe AM, Clunie S, Cox GF, Lurie PR, Canter CE, Hsu DT, Morrow WR, Colan SD. Outcome predictors in pediatric hypertrophic cardiomyopathy. *N Engl J Med* (to be submitted September 2011 - final draft distributed) (2011).
237. Wilkinson J, Salbert BA, Lowe AM, Connuck DM, Towbin JA, Colan SD, Cox GF, Sleeper LA, Cadregari ER, Clunie SC, Messere J, **Lipshultz SE**. Outcomes in children with Noonan syndrome and hypertrophic cardiomyopathy: a study from the Pediatric Cardiomyopathy Registry. *J Am Coll Cardiol* (JACC122310-5078-1/11/11-minor revision requested, 2/18/11-revised manuscript submitted-under review) (2011).
238. Sleeper LA, Towbin JA, Colan SD, Hsu DT, Lemler M, Messere JA, Clunie S, Cuniberti L, Servedio D, Rodgers-Augustyniak L, Lowe AM, Orav EJ, **Lipshultz SE**. Impaired functional status in children with cardiomyopathy: A report from the pediatric cardiomyopathy registry. *N Engl J Med* (to be submitted August 2011 – draft #8 reviewed April 2011) (2011).
239. Adams MJ, Ng AK, Mauch P, Lipsitz SR, Winters P, **Lipshultz SE**. Physical health related quality of life is predicted by peak oxygen consumption and declines over time in Hodgkin lymphoma survivors treated with mediastinal radiotherapy. *J Clin Oncol*. To be submitted 8/11 (10 drafts reviewed) (2011).
240. Tisma-Dupanovic S, Zareba W, McClintic B, **Lipshultz SE**, Andrews M, Moss AJ. Electrocardiographic phenotype-genotype correlations in infants with long-QT Syndrome. *J Am Coll Cardiol*. To be submitted in 2011 - draft forms reviewed since 2007 (2011).
241. Asselin BL, Devidas M, Wang C, Pullen J, Borowitz MJ, Hutchison R, **Lipshultz SE**, Camitta BM. Effectiveness of high dose methotrexate in T-cell lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404). *Blood* 118(4):874-83. 2011 Apr 7. [Epub ahead of print] (#2010/292615-Accepted 12/10. Published Online First at Blood/First Edition-1/10/11) (PMID: 21474675) (2011).
242. **Lipshultz SE**, Shearer WT, Thompson B, Rich KC, Cheng I, Orav EJ, Kumar S, Pignatelli RH, Bezold LI, LaRussa P, Starc TJ, Glickstein JS, O'Brien S, Cooper ER, Wilkinson JD, Miller TL, Colan SD. Cardiac effects of antiretroviral therapy in HIV-negative infants born to HIV-positive mothers: NHLBI CHAART-1 (National Heart, Lung, and Blood Institute Cardiovascular Status of HAART Therapy in HIV-Exposed Infants and Children Cohort Study). *J Am Coll Cardiol* 57(1):76-85. ISSN 0735-1097, doi:10.1016/j.jacc.2010.08.620. PMID: 21185505. (2010).
243. **Lipshultz SE**, Lipsitz SR, Lopez-Mitnik G, Landy DC, Hinkle AS, Constine LS, French CA, Rovitelli AM, Proukou C, Adams MJ, Miller TL. Cardiac status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy. *J Clin Oncol* (JCO/2010/337907-submitted 12/10, revision requested 3/11, revision submitted 5/11, second revision requested 6/21/11) (2011).
244. Milton-Miller A, Lopez-Mitnik G, Somarriba G, Lipsitz SR, Hinkle AS, Constine LS, **Lipshultz SE**, Miller TL. Exercise capacity in long-term survivors of pediatric cancer. *J Clin Oncol* (submitted 2/11-under review) (2011).

245. Pietra B, Kantor P, Bartlett H, Chin C, Canter C, Larsen R, Edens E, Colan S, Towbin J, **Lipshultz SE**, Kirklin J, Naftel D, Sleeper L, Hsu D. Clinical factors associated with UNOS status and outcome after listing for heart transplantation in children with dilated cardiomyopathy. *Circulation* (Minor revision submitted 4/11, second set of minor revisions requested 6/11, second revision submitted 9/11-under review) (2011).
246. Foerster SR, Canter CE, Cinar A, Sleeper LA, Webber SA, Pahl E, Kantor PF, Alvarez JA, Colan SD, Jefferies JL, Lamour JM, Margossian R, Messere JE, Rusconi PG, Shaddy RE, Towbin JA, **Lipshultz SE**. Ventricular remodeling and survival are more favorable for myocarditis than for idiopathic dilated cardiomyopathy in childhood: An outcomes study from the Pediatric Cardiomyopathy Registry. *Circ Heart Fail* 3(6):689-97. Published online Sep 10, 2010: doi: 10.1161/CIRCHEARTFAILURE.109.902833. PMID: 20833772. (2010).
247. Sokol KC, Rusconi P, Harmon WG, Bublik N, **Lipshultz SE**. Advances in hypertrophic cardiomyopathy during childhood. *US Pediatrics* 4(1):24-26 (2008).
248. Berridge BR, Pettit S, Walker DB, Jaffe AS, Schultze AE, Herman E, Reagan WJ, **Lipshultz SE**, Apple FS, York MJ. A transformational approach to detecting drug-induced cardiac injury with cardiac troponins: consensus and recommendations from the Cardiac Troponins Biomarker Working Group of the Health and Environmental Sciences Institute. *Am Heart J* 158(1):21-9. (2009). PMID: 19540388.
249. Goldberg J, **Lipshultz SE**. Cardiac late effects after childhood cancer. *Curr Cancer Ther Rev*. (Invited article) (2011).
250. Hlaing WM, Messiah SE, **Lipshultz SE**, Ludwig DA. Obesity and length of hospital stay in children: a retrospective review of Florida Agency for Health Care Administration data. *Prog Pediatr Cardiol* 31:67-72. (doi:10.1016/j.ppedcard.2010.11.011). (2011).
251. Singh TP, Sleeper LA, **Lipshultz SE**, Cinar A, Canter CE, Webber SA, Bernstein D, Pahl E, Alvarez JA, Wilkinson JD, Towbin JA, Colan SD. Association of left ventricular dilation at listing for heart transplant with post-listing and early post-transplant mortality in children with dilated cardiomyopathy. *Circulation: Heart Failure* 2(6):591-8. Published online before print on September 28, 2009, doi: 10.1161/CIRCHEARTFAILURE.108.839001 (2009).
252. Singla A, **Lipshultz SE**, Fisher S. Midventricular obstructive hypertrophic cardiomyopathy during pregnancy complicated by preeclampsia and acute myocardial infarction: a case report. *Congenit Heart Dis* 2011 May;6(3):257-61. 2011 Mar 21. Doi: 10.1111/j.1727-0803/2010/00453.x. [Epub ahead of print]. PMID: 21418527. (2011).
253. **Lipshultz SE** (Chair of Proposed Writing Group), et al. Approved and commissioned - American Heart Association Scientific Statement on Cardiovascular Disease in Childhood Cancer. *Circulation* (Invited) (December 2008). On 6/10/09: MS ID#: STATEMENTAHA/2009/005363. MS TITLE: Long Term Cardiovascular Health and Monitoring of Children Receiving Chemotherapy: Current Knowledge. Sponsored: Cardiovascular Disease in the Young Council, Co-sponsored: Epidemiology and Prevention Council. On July 9 the Manuscript Oversight committee (MOC) suggested co-sponsorship by the Council on Clinical Cardiology and expansion to include adult patients. (Kathryn Taubert, Donna Stephens, Craig Sable, Paul Matherne, and Mary Cushman). Approved and commissioned: 9/2010 according to Dr. Sable on 10/2/10.
254. Cox G, **Lipshultz SE**, et al. American College of Medical Genetics Clinical Practice Guidelines for Management of Pediatric Cardiomyopathy. (Invited) (December 2008, second round of development 2/10).
255. Wilkinson JD, Landy DC, Colan SD, Towbin JA, Sleeper LA, Orav EJ, Cox GF, Canter CE, Hsu DT, Webber SA, **Lipshultz SE**. The pediatric cardiomyopathy registry and heart failure: Key results from the first 15 years. *Heart Fail Clin* 6(4):401-13. (PMID: 20869642). (2010).

256. **Lipshultz SE**, Wilkinson JD, Messiah SE, Miller TL. Clinical research directions in pediatric cardiology. *Curr Opin Pediatr* 21:585-593. 2009 Jul 3. [Epub ahead of print]. Post Author corrections, doi: 10.1097/MOP.0bo13e32832e48df. (Cardiovasc Med Section – Ed. Huhta J.) (2009). PMID: 19584723
257. Messiah SE, Arheart KL, Natale RA, Hlaing WM, **Lipshultz SE**, Miller TL. Body mass index, waist circumference, and cardiovascular disease risk factors among preschool-age children in the United States: an analysis of 1999-2008 NHANES data. *Am J Prevent Med* (submitted). (2011).
258. Goldberg JM, Scully RM, Sallan SE, **Lipshultz SE**. Cardiac failure 30 years after treatment containing anthracycline for childhood acute lymphoblastic leukemia. *Amer J Hematol/Oncol*. (In revision) (2011).
259. Thompson KL, Rosenzweig BA, Zhang J, Knapton AD, Honchel R, **Lipshultz SE**, Retief J, Sistare FD, Herman EH. Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in rats. *Cancer Chemother Pharmacol* 66(2):303-314. 2009 Nov 14 (Epub ahead of print) [10.1007/s00280-009-1164-9 - PMID: 19915844] (July 2010).
260. Eddine AC, Alvarez O, **Lipshultz SE**, Kardon R, Arheart K, Swaminathan S. Ventricular structure and function in children with sickle cell anemia: a case-control study using conventional and tissue Doppler echocardiography. To be submitted to *Am J Cardiol* (second draft 5/09, third draft 9/12/09, fourth draft 1/28/10, 9th draft-10/10, most recent draft-6/11). (2011).
261. Messiah SE, Miller TL, **Lipshultz SE**, Bandstra ES. Potential latent effects of prenatal cocaine exposure on growth and the risk of cardiovascular and metabolic disease in childhood. *Prog Pediatr Cardiol*. 31(1):59-65. (PMID: 21318092, PMCID: PMC3037026). (2011).
262. Vila CK, Miller TL, Scott GB, Wilkinson JD, Zebrowski J, Poirier MC, Malker VE, Colan SD, Brosco JP, **Lipshultz SE**. Taking HAART: Evidence for the long-term effects of In Utero Exposure to antiretroviral therapy for Human Immunodeficiency Virus infection. (to be submitted to *N Engl J* - final draft-5/1/11) (2011).
263. Seifert SM, Schaechter JL, Hershorin ER, **Lipshultz SE**. Health effects of energy drinks on children, adolescents, and young adults. *Pediatrics* 127(3):511-28 (Special Article). Epub 2011 Feb 14. PMID: 21321035. (2011).
264. Ebb D, Meyers P, Grier H, Bernstein M, Gorlick R, **Lipshultz SE**, Krailo M, Devidas M, Barkauskas DA, Siegal GP, Ferguson WS, Letson GD, Marcus K, Goorin A, Beardsley P, Marina N. Phase II trial of trastuzumab in combination with cytotocix chemotherapy for treatment of metastatic osteosarcoma with HER2 overexpression: a report from the children's oncology group. *J Clin Oncol* (Submitted 6/11/11 – JCO/2011/374546) (2011).
265. Alvarez JA, Orav EJ, Wilkinson JD, Sleeper LA, Fleming LE, Lee DJ, Rusconi PG, Colan SD, Hsu DT, Canter CE, Webber SA, Cox GF, Jefferies JL, Towbin JA, **Lipshultz SE**, for the Pediatric Cardiomyopathy Registry Investigators. Competing risks for death and cardiac transplantation in children with dilated cardiomyopathy: Results from the Pediatric Cardiomyopathy Registry. *Circulation* 124(7):814-823. [PMID: 21788591] (2011).
266. Larsen RL, Canter CE, Naftel DC, Tressler M, Rosenthal DN, Blume ED, Mahle WT, Yung D, Morrow WR, Orav EJ, Wilkinson JD, Towbin JA, **Lipshultz SE**. The impact of heart failure severity at time of listing for cardiac transplantation on survival in pediatric cardiomyopathy. *J Heart Lung Transplant* 30(7):755-60, 2011 Mar 16 [Epub ahead of print] PMID: 21419658 (2011).
267. Miller TL, Somarriba G, Orav EJ, Mendez AJ, Neri D, Schaefer N, Forster L, Goldberg R, Scott GB, **Lipshultz SE**. Biomarkers of vascular dysfunction in children infected with human immunodeficiency virus-1. *J Acquir Immune Defic Syndr*. 55(2):182-8. 2010 Jun 7. [Epub ahead of print] PMID: 20531209. (2010).

268. Fisher SD, Kanda BS, Miller TL, **Lipshultz SE**. Cardiovascular disease and therapeutic drug related cardiovascular consequences in HIV infected patients. *Am J Cardiovasc Drugs*. (invited 9/2/09, Submitted 5/10, assigned to editor 6/3/10 and sent for peer review, Revision requested 7/10, Revised manuscript submitted 6/15/11 – under review. CVD-C-10-00135) (2011).
269. Bezold LI, O'Brien S, Pignatelli RH, Eidem BW, Thompson B, Cheng I, Ludwig D, Wilkinson JD, **Lipshultz SE**. NHLBI CHAART-I Writing Group: Frequency of left ventricular systolic abnormalities versus diastolic abnormalities. Status-analyses completed, Manuscript due 8/11.
270. **Lipshultz SE**, Wilkinson JD, O'Brien S, Bezold LI, Thompson B, Cheng I, Colan SD, Ludwig D, Lopez-Mitnik G. CHAART-I Writing Group: Systolic function by trimester of ART exposure. Status-analyses active, Manuscript due 8/11.
271. Miller TL, Ludwig D, Lopez-Mitnik G, Neri-Almeida D, Wilkinson JD, **Lipshultz SE**. CHAART-I Writing Group: Nutritional status of ART exposed HIV-uninfected infants. Status-Analyses completed, Manuscript due 8/11.
272. Wilkinson JD, Cheng I, Thompson B, Rifai N, Shearer WT, Rich KC, Colan SD, Miller TL, Orav EJ, **Lipshultz SE**. Cardiac biomarkers in assessment of cardiac structure and function in children exposed to the human immunodeficiency virus in utero. *Am Heart J* (final draft submitted to authors 6/11. To be submitted 8/11).
273. Webber SA, **Lipshultz SE**, Sleeper LA, Lu M, Wilkinson JD, Addonizio LJ, Canter CE, Colan SD, Everitt MD, Jefferies JL, Kantor P, Lamour JM, Lu M, Margossian R, Pahl E, Rusconi P, Towbin JA. Outcomes of restrictive cardiomyopathy in childhood and the influence of phenotype: A report from the pediatric cardiomyopathy registry. *Circulation* (Submitted 8/11- under review) (2011).
274. Morris SM, **Lipshultz SE**, Callicott R, Desai V, Herman EH. Cardiac stimulants during development: Methyphenadate effects on developing primate cardiac function, mitochondrial status and injury. Manuscript is being drafted. (2011).
275. Adams MJ, Dozier A, Shore RE, **Lipshultz SE**, Schwartz RG, Constine LS, Pearson TA, Stoval M, Winters P, Fisher SG. Breast cancer risk 55+ years after irradiation for an enlarged thymus and its implications for early childhood medical irradiation today. *Cancer Epidemiol Biomarkers Prev*. 19(1):48-58 (2010). (PMID: 20056622)
276. **Lipshultz SE**, Williams PL, Shearer WT, Rich K, Leister E, Hazra R, Kaltman J, Jacobson D, Dooley L, Wilkinson JD, Scott G, Colan SD, for the Pediatric HIV/AIDS Cohort Study (PHACS). Increased left ventricular and aortic dimensions in long-term multagent antiretroviral therapy (ART)-treated HIV-infected children: The NIH multicenter pediatric HIV/AIDS Cohort Study (PHACS). To be submitted to *Circulation* (Sixth draft distributed 6/11) (2011).
277. Rusconi PG, Ludwig DA, Ratnasamy C, Mas R, Harmon WG, Colan SD, **Lipshultz SE**. Serial measurements of NT-proBNP as markers of left ventricular systolic function and remodeling in children with heart failure. *Am Heart J* 160(4):776-83. (doi: 10.1016/j.ahj.2010.07.012) PMID: 20934575. (2010).
278. Rao A, **Lipshultz SE**, Herman EH. Cardiac biomarkers across species. To be submitted to *Cardiovasc Tox* (First draft distributed 10/09) (2011).
279. Herman E, Knapton AD, Rosen E, Zhang J, Estis J, Agee SJ, Lu QA, Todd JA, **Lipshultz SE**. Baseline serum cardiac troponin I concentrations in sprague-dawley, spontaneous hypertensive, wistar, wistar-kyoto, and fisher rats as determined with an ultrasensitive immunoassay. *Toxicol Pathol* 39(4):653-63. 2011 May 10. [Epub ahead of print] (PMID: 21558468) (2011).
280. Petricoin EF, Ross MM, Zhou W, Tamburro D, Luchini A, Liotta L, Scully RE, Miller TL, Sallan SE, **Lipshultz SE**. Candidate serum biomarkers of anthracycline-induced cardiotoxicity in pediatric leukemia: results of nanoparticle-capture mass spectrometry. To be submitted to the *J Clin Oncol* (first draft distributed 10/09, fourth version 1/10, fifth version 2/10) (2011).

281. **Lipshultz SE**, Miller TL, Lipsitz SR, Neuberg DS, Dahlberg SE, Colan SD, Silverman LB, Cushman LL, Henkel JM, Sallan SE, for the Dana-Farber Cancer Institute Acute Lymphoblastic Consortium. Late cardiac status in long-term survivors of childhood high-risk acute lymphoblastic leukemia 8 years after continuous or bolus infusion of doxorubicin: The Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia 91-01 randomized trial. *Circulation*. (submitted 8/11-under review) (2011).
282. **Lipshultz SE**, Shearer WT, Thompson B, Rich KC, Cheng I, Milton AN, Orav EJ, Kumar S, Pignatelli RH, Bezold LI, LaRussa P, Starc TJ, Glickstein J, O'Brien S, Cooper ER, Wilkinson JD, Miller TL, Colan SD. Cardiac effects of antiretroviral therapy in HIV-infected children: The NHLBI CHAART-2 cohort study. To be submitted to *N Engl J Med* (First draft –September 2009) (2011).
283. Franco VI, Henkel JM, Miller TL, **Lipshultz SE**. Cardiovascular effects in childhood cancer survivors treated with anthracyclines. *Cardiol Res Pract* 2011 Feb 10;2011:134679 (PMID: 21331374) (2011).
284. Torres SM, Scully RE, Lipsitz SR, Miller TL, Sallan SE, Walker VE, **Lipshultz SE**. Mutational analysis of the mitochondrial tRNA genes and flanking regions in lymphocytes from long-term pediatric cancer survivors given anthracycline chemotherapy for acute lymphoblastic leukemia. To be submitted to the *J Clin Oncol*. (First draft distributed 9/09, second draft distributed 2/10) (2011).
285. **Lipshultz SE**, Miller TL, Scully RE, Lipsitz SR, Rifai N, Silverman LB, Colan SD, Neuberg DS, Dahlberg SE, Asselin BL, Athale U, Clavell LA, Larsen E, Laverdiere C, Michon B, Schorin MA, Sallan SE. Changes in cardiac biomarkers during doxorubicin treatment in children with high-risk acute lymphoblastic leukemia: Associations with long-term echocardiographic outcomes. Submitted to the *J Clin Oncol* (May 2010-submitted, 6/10-accepted with minor revision, revision submitted 9/10, second revision requested 11/10, submitted 3/2/11, third revision requested 4/11, submitted 6/11, under review) (2011).
286. **Lipshultz SE**, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL, Barry EV, Asselin BL, Athale U, Clavell LA, Larsen E, Moghrabi A, Samson Y, Michon B, Schorin MA, Cohen HJ, Neuberg DS, Orav EJ, Colan SD. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomized, multicentre trial. *Lancet Oncol* 11:950-61. Fast-Track (Published online ahead of print 9/16/10. Pages 1-12. doi: 10.1016/51470-2045(10)70204-7). PMID: 20850381. (2010).
287. **Lipshultz SE**, Mas K, Fisher SD, Henkel J, Franco VI, Miller TL. HAART to heart: the risk of cardiovascular disease in HIV-infected individuals. *Expert Rev Anti-infective Therap*. (invited 3-7 K words, Final draft-8/15/11 – to be submitted 9/11) (2011).
288. **Lipshultz SE**, Adams MJ. Cardiotoxicity after childhood cancer: beginning with the end in mind. *J Clin Oncol* 28(8):1276-81. Published ahead of print on February 8, 2010 as a JCO Early Release Article (10.1200/JCO.2009.26.5751). (<http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2009.26.5751>). (PMID: 20142585) (2010).
289. Adams MJ, Shore RE, Dozier A, **Lipshultz SE**, Schwartz RG, Constine LS, Pearson TA, Stovall M, Thevenet-Morrison K, Fisher SG. Thyroid cancer risk 40+ years after irradiation for an enlarged thymus: an update of the Hempelmann cohort. *Radiat Res* 174(6):753-762. (2010 Oct 26. [Epub ahead of print]). NIHMSID # 256757. PMID: 20977298, 21128799. (2010).
290. Miller TL, Orav EJ, Wilkinson JD, Sleeper LA, Towbin JA, Colan SD, Hsu DT, Canter CE, Webber SA, **Lipshultz SE**. Nutritional status is associated with cardiac outcomes and mortality

- in children with idiopathic dilated cardiomyopathy. (oral presentation at AHA 2009 analyses complete, first draft of manuscript in progress) (2011).
291. Pahl E, Sleeper LA, Canter CE, Hsu DT, Lu M, Webber SA, Colan SD, Kantor PF, Everitt MD, Towbin JA, Jefferies JL, Kaufman BD, Wilkinson JD, Towbin JE, **Lipshultz SE**. Incidence of and risk factors for sudden cardiac death in children with dilated cardiomyopathy: a report from the Pediatric Cardiomyopathy Registry. (Submitted to JACC-3/11, revision requested-4/11, revised submission 5/11, 8/26/11-accepted with minor revision requested – In revision) (2011).
 292. O'Brien S, Sasaki N, Eidem BW, Colan SD, Shearer WT, Cheng I, Thompson B, Wilkinson JD, Miller TL, Orav EJ, Pignatelli RH, Bezold LI, Rich KC, Kumar S, LaRussa P, Starc TJ, Glickstein J, McIntosh K, Cooper E, **Lipshultz SE**. Antiretroviral therapy and HIV-associated left ventricular diastolic dysfunction in uninfected ART-exposed infants born to HIV-infected women: the prospective NHLBI CHAART-1 study. *N Engl J Med* (to be submitted 8/11, 8th draft distributed 5/15/11) (2011).
 293. Trachtenberg BH, Landy DC, Franco VI, Henkel JM, Pearson EJ, Miller TL, **Lipshultz SE**. Anthracycline-associated cardiotoxicity in survivors of childhood cancer. *Pediatr Cardiol*. 32(3):342-353. 2011 Jan 9. [Epub ahead of print]. (PMID: 21221562). (2011).
 294. Messiah SE, Arheart KL, **Lipshultz SE**, Miller TL. Perinatal etiology of cardiovascular disease risk factors in preschool age children in the United States: an analysis of 1999-2006 data. Targeted for *J Pediatr*. Submission for 8/11.
 295. Messiah SE, Miller TL, **Lipshultz SE**, Accornero VH, Bandstra ES. Assessing latent effects of prenatal cocaine exposure on growth and the risk of cardiometabolic disease risk in late adolescence: Design and methods utilizing a longitudinal study. Final draft-3/1/11. *J Addictive Dis*. Submitted - 3/2011 – under review.
 296. Messiah SE, Arheart KL, Ludwig D, Miller TL, **Lipshultz SE**, Bandstra ES. Impact of prenatal cocaine exposure on anthropometric growth from birth to age two. *Pediatrics*-subm for-8/2011.
 297. Vrooman LM, Neuberg DS, Supko JG, Kutok JL, Dahlberg S, Stevenson KE, O'Brien J, Asseelin BL, Athale UH, Clavell L, Kelly KM, Laverdiere C, **Lipshultz SE**, Michon B, Schorin M, Cohen HJ, Sallan SE, Silverman LB. Dexamethasone and individualized dosing of L-asparaginase in the treatment of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocol 00-01. *Blood* (Submitted 4/2010, revision requested-12/10 resub-BLOOD.2010/281006 (2010).
 298. Nada A, Paredes A, Eloff B, Berridge BX, Klein C, Gottfridsson C, Colette S, Dota C, Gutstein D, Gintant G, Geiger MJ, Carlson G, Gussak L, Finkle JZ, Karanian J, Killeen M, Fisman M, Harlow P, Schuette P, Sager P, Kleiman R, Sanhai W, Rodriguez I, **Lipshultz SE**. HESI guidelines for electrocardiographic monitoring of cardiotoxicity in pharmaceutical trials. (version 12 sent to authors 5/2011). To be submitted to *Am Heart J* ~7/11. (2011).
 299. Parzen M, Fitzmaurice G, Lipsitz S, Ibrahim J, **Lipshultz S**. Numerical approximations in weighted estimating equations for regression models with missing continuous covariates. Submitted to the *Journal of Statistical Planning and Inference*. (2009).
 300. Jefferies JL, Colan SD, Sleeper LA, Pahl E, Kantor PF, Everitt MD, Webber SA, Kaufman BD, Lamour JM, Canter CE, Hsu DT, Addonizio L, **Lipshultz SE**, Towbin JA, for the Pediatric Cardiomyopathy Registry Investigators. Outcome and risk stratification for children with left ventricular noncompaction: Findings from the pediatric cardiomyopathy registry. *Circulation* (third draft 6/11, scheduled for submission-8/11) (2011).
 301. Ricci M, Hammond HL, Nathanson L, Rodriguez MM, Vatta M, **Lipshultz SE**, Lincoln J. Identifying myocardial gene expression profiles in hypoplastic left heart syndrome and age-matched normal controls. *J Am Coll Cardiol* (submitted 2/11-in review) (2011).

302. Dadlani GH, Harmon WG, Perez-Colon E, Sokoloski MC, Wilmot I, **Lipshultz SE**. Diagnosis and screening of hypertrophic cardiomyopathy in children. *Prog Pediatr Cardiol* 31(1):21-27 (doi:10.1016/j.ppedcard.2010.11.005) (2011).
303. Schwartz CL, Wexler LH, Devidas M, Teot LA, Goorin AM, Steinherz L, Gebhardt M, **Lipshultz SE**, Healey JH, Sato JK, Miser JS, Meyers PA, Wang C, Krailo MD, Grier HE, Bernstein ML. Intensified chemotherapy for newly-diagnosed non-metastatic osteogenic sarcoma: a study from the Children's Oncology Group. *Cancer* (submitted 8/11-in review) (2011).
304. Vrooman LM, Neuberg DS, Stevenson KE, Asselin BL, Athale UH, Clavell L, Cole PD, Kelly KM, Larsen EC, Laverdiere C, Michon B, Schorin M, Schwartz CL, Cohen HJ, **Lipshultz SE**, Silverman LB, Sallan SE. The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. *Eur J Cancer* 2011 Jun;47(9):1373-9. Epub 2011 Apr 20 (2011).
305. de la Cruz-Munoz N, Messiah SE, Arheart KL, Lopez-Mitnik G, **Lipshultz SE**, Livingstone A. Bariatric surgery significantly decreases the prevalence of type 2 diabetes mellitus and pre-diabetes among morbidly obese multiethnic adults: long-term results. *J Am Coll Surg* 2011 Apr;212(4):505-11; discussion 512-3. (published online before print, commentary and CME assigned) (PMID: 21463779) (2011).
306. Delgado-Borrego A, Smith L, Jonas MM, Hall CA, Negre B, Ogradowicz M, Raza R, Jordan SH, Ludwig DA, Miller TL, **Lipshultz SE**, Gonzalez-Peralta R, Chung RT. Expected and actual case ascertainment and treatment rates for hepatitis C-positive children in the US and in Florida: epidemiological evidence from a nationwide and a statewide survey. *J Pediatr* (submitted 9/11-under review) (2011).
307. Herman EH, Knapton A, Rosen E, Thompson K, Rosenzweig B, Estis J, Agee S, Lu QA, Todd JA, **Lipshultz SE**, Hasinoff B, Zhang J. A multi-faceted evaluation of imatinib-induced cardiotoxicity in the rat. *Toxicol Pathol* 39(4):653-63. (PMID: 21558468) (2011).
308. **Lipshultz SE**, Wilkinson JD, Colan SD, Towbin JA. Introduction. *Prog Pediatr Cardiol*. 31(1):1 (doi:10.1016/j.ppedcard.2010.11.001). (2011).
309. Little MP, Azizova TV, Bazyka D, Bouffler SD, Cardis E, Chekin S, Chumak VV, Cucinotta FA, de Vathaire F, Hall P, Harrison JD, Hildebrandt G, Ivanov V, Kascheev VV, Klymenko SV, Kreuzer M, Ozasa K, Schneider T, Tapio S, Taylor AM, Tzoulaki I, Vandoolaeghe WL, Wakeford R, Zhang W, **Lipshultz SE**. Meta-analysis of circulatory disease from exposure to low-level ionizing radiation and estimates of potential population risks. *Brit Med J* (revised version resubmitted-5/11-in review). (2011).
310. Landy DC, Miller TL, Lopez-Mitnik G, Lipsitz SR, Hinkle AS, Constine LS, French CA, Rovitelli AMK, Adams MJ, **Lipshultz SE**. Aggregating traditional cardiovascular disease risk factors to assess the cardiometabolic health of childhood cancer survivors: an analysis from the cardiac risk factors in childhood cancer survivors study. *Cancer Epidemiol Biomarkers Prev* (submitted 8/11-under review) (2011).
311. De La Cruz-Munoz N, Lopez-Mitnik G, Arheart KL, Livingstone A, **Lipshultz SE**, Messiah SE. Bariatric surgery significantly improves cardiometabolic disease risk among morbidly obese multiethnic adolescents. *J Pediatr* (Submitted 8/11 – under review) (2011).
312. **Lipshultz SE**, Colan SD, Towbin JA, Wilkinson JD. Introduction. *Prog Pediatr Cardiol* 31(2):73 (doi:10.1016/j.ppedcard.3011.02.001). (2011).
313. Landy DC, Miller TL, Mitnik GL, Lipsitz SR, Hinkle AS, Constine LS, Adams MJ, French CA, Rovitelli AM, Proukou C, Wilkinson JD, **Lipshultz SE**. LV structure, lv function, and serum nt-

- probnp in childhood cancer survivors without anthracycline or cardiac radiation exposures. *Prog Pediatr Cardiol*. 31(2):141-142 (doi:10.1016/j.ppedcard.2011.02.015) (2011).
314. Wilkinson JD, Zebrowski JP, Hunter JA, Mensah GA, Ezzati M, Forouzanfar MH, Colan SD, Towbin JA, Hsu DT, Mocumbi AO, Canter CE, Weintraub RG, Burch M, **Lipshultz SE**. Assessing the global and regional impact of primary cardiomyopathies: the Global Burden of Diseases, Injuries and Risk Factors (GBD 2010) Study. *Prog Pediatr Cardiol*. 32(1):55-63 (2011).
 315. Messiah SE, Lopez-Mitnik G, Winegar D, Sherif B, Arheart KL, Reichard KW, Michalsky MP, **Lipshultz SE**, Miller TL, Livingstone AS, De La Cruz-Muñoz N. Changes in weight and comorbidities among morbidly obese adolescents undergoing bariatric surgery: 1-year results from the bariatric outcomes longitudinal database (BOLD). *J Am Med Assoc* (submitted 6/11/11 – under review) (2011).
 316. Dunn ME, Coluccio D, Hirkaler G, Mikaelian I, Nicklaus R, **Lipshultz SE**, Doessegger L, Reddy M, Singer T, Geng W. The complete pharmacokinetic profile of serum cardiac troponin I in the rat and the dog. *Toxicol Sci* 2011 Jul 20. [Epub ahead of print] [PMID: 21558468] (2011).
 317. Dunn M, Coluccio D, Zabka TS, Gopalakrishnan G, Hirkaler G, Geng W, Nicklaus R, **Lipshultz SE**, Doessegger L, Saladino BH, Singer T, Mikaelian I. Myocardial mononuclear infiltrates are not associated with increased serum cardiac troponin I in cynomolgus monkeys. *Toxicol Pathol* (Submitted 6/11, revision requested 7/11, revision under review 8/11) (2011).
 318. Mikaelian I, Dunn M, Coluccio D, Geng W, Nicklaus R, Reddy M, **Lipshultz SE**, Suter-Dick L, Doessegger L, Singer T, Zabka T. Serum cardiac troponin I as a marker of cardiotoxicity in the rat. *Toxicol Pathol* (Submitted 7/11 – under review) (2011).
 319. Dadlani G, Harmon W, O'Brien R, Casadonte JR, Sokoloski M, Stapleton G, Crawford M, Turpin D, Epstein M, Miller TL, Messiah SA, Wilkinson JD, **Lipshultz SE**. Community based cardiovascular screening in adolescents: identification of overweight, obesity, hypertension, and potential causes of sudden cardiac death. *Am J Cardiol* (2nd draft-in revision) (2011).
 320. Seifert SM, Schechter JL, Hershorin ER, **Lipshultz SE**. Concerns about energy drink consumption by children, adolescents, and young adults. *Pediatr for Parents*. Accepted 7/10/11-In press. (2011).
 321. Mas KM, Miller TL, Wilkinson JD, **Lipshultz SE**. Effects of antiretroviral therapy in early childhood and fetal life. *AIDS Clin Res (Special Issue on Pharmacology of Antiretroviral Agents: HIV)*. Date of publication: 9/13/11.
 322. Jean-Pierre P, Winters P, Ahles T, Antoni M, Armstrong D, Penedo F, **Lipshultz SE**, Miller TL, Fiscella K. Prevalence of self-memory problems in adult cancer survivors: a national cross-sectional study. *J Oncol Practice* (Accepted – In press) (JOP-0111-000231R) (2011).
 323. Shehadeh LA, Ricci M, Hammond HL, Nathanson L, Rodriguez MM, **Lipshultz SE**, Lincoln J. Exon array analysis to identify biomarkers of early stage hypoplastic left heart syndrome. *Circulation* (Second draft – to be submitted shortly) (2011).
 324. **Lipshultz SE**. Heart failure with HIV infection. *Evidence-Based Medicine* (accepted-in press) 16(5):1-4 (2011).
 325. De La Cruz-Munoz N, Lopez-Mitnik G, Arheart KL, Livingstone AS, **Lipshultz SE**, Messiah SE. Bariatric surgery significantly improves cardiometabolic disease risk among morbidly obese hispanic adults. To be submitted to *Circulation* (Second draft distributed 8/24/11) (2011).
 326. Foster SB, Lu M, Glaze DG, Reuben JM, Harris LL, Cohen EN, Lee BN, Paul ME, Schwarzwald HL, McMullen-Jackson C, Clark C, Armstrong DF, Brouwers PY, Miller TL, Colin AA, Scott GB, Shahzeidi S, Willen E, Asthana D, **Lipshultz SE**, Thompson B, Shearer WT. Interactions of cytokines, sleep patterns, and neurocognitive function in older children and adolescents with HIV infection. *J Allerg Clin Immunol* (submitted 8/11 – under review)(2011).

327. Siberry GK, Leister E, Jacobson D, Foster SB, Seague G, **Lipshultz SE**, Paul ME, Purswani M, Colin AA, Scott G, Shearer WT. Increased incidence of asthma and atopic dermatitis in perinatally HIV-infected children and adolescents in the pediatric HIV/AIDS cohort study (PHACS). *J Allerg Clin Immunol* (submitted 8/11 – under review)(2011).
328. Wilkinson JD, Williams P, Leister E, Zeldow B, Shearer WT, Colan SD, Siberry G, Dooley LB, Scott G, Rich K, **Lipshultz SE**, for the Pediatric HIV/AIDS Cohort Study (PHACS). Cardiac biomarkers in HIV-exposed uninfected children: the pediatric HIV/AIDS cohort study (PHACS) surveillance monitoring for antiretroviral toxicities (SMARTT) Protocol. To be submitted to *Circulation* (second draft distributed-8/24/11) (2011).
329. Barach PR, Jacobs JP, Laussen PC, **Lipshultz SE**. Outcomes analysis, quality improvement, and patient safety for pediatric and congenital cardiac disease: theory, implementation and applications. *Prog Pediatr Cardiol* (Accepted-in press) (2011).
330. Kantor PF, Rusconi P, **Lipshultz S**, Mital S, Wilkinson JD, Burch M. Current applications and future needs for biomarkers in pediatric cardiomyopathy and heart failure: summary from the second international conference on pediatric cardiomyopathy. *Prog Pediatr Cardiol* 32(1):11-14 (2011).
331. Lipshultz SE, Colan SD, Towbin JA, Wilkinson JD. Introduction. *Prog Pediatr Cardiol* 32(1):1 (2011).
332. Herman EH, Knapton A, Hiraragi H, **Lipshultz SE**, Zhang J. Effect of sex on the severity of doxorubicin-induced cardiac and renal toxicity in adult spontaneously hypertensive rats. *Cancer Chemother Pharmacol*. (to be submitted 9/11 – final approvals) (2011).
333. Hirake D, Franco VI, Henkel JM, Miller TL, **Lipshultz SE**. Strategies for preventing cardiotoxicity in children treated for cancer. *Future Cardiol* (invited-submitted 9/11) (2011).
334. Diamond MB, Franco VI, Miller TL, **Lipshultz SE**. Anthracycline treatment in childhood cancer survivors: preventing and treating the adverse effects in the heart. *Curr Cancer Ther Rev*. (invited-submitted 9/11) (2011).
335. Torres SM, Miller TL, Wilkinson JD, Walker VE, **Lipshultz SE**. Cardiac structure and function related to mutational analysis of the mitochondrial tRNA genes and flanking regions in lymphocytes from HIV-infected children: the NHLBI CHAART-II study. To be submitted to the *J AIDS*. (First draft -9/11) (2011).
336. Messiah SE, **Lipshultz SE**, Miller TL, Accornero VH, Glavach MK, Bandstra ES. Assessing latent effects of prenatal cocaine exposure on growth and risk of cardiometabolic disease in late adolescence: design and methods. *J Addictive Dis*. (submitted 8/11 – under review) (2011).

Active and Approved NIH Writing Groups with Manuscripts in Preparation:

1. **Lipshultz SE**, Wilkinson JD, Thompson B, Cheng I. CHAART I mtDNA
2. **Lipshultz SE**, Colan SD, Wilkinson JD, Thompson BT, Cheng I. Contribution of HIV infection and ART exposure to cardiac dysfunction (CHAART II vs. CHAART I)
3. **Lipshultz SE**, Wilkinson JD, Thompson B, Cheng I, Colan SD, Walker V, Bezold LI. CHAART II mtDNA with echocardiography
4. **Lipshultz SE**, Wilkinson JD, Bezold LI, Thompson B, Cheng I. CHAART II biomarkers vs. systolic function vs. mtDNA
5. Colan SD, **Lipshultz SE**, et al. Sudden death in HCM
6. Cox G, **Lipshultz SE**, et al. Mitochondrial disorders: characteristics and outcome from the pediatric cardiomyopathy registry.
7. **Lipshultz SE**, Chinook, et al. Utilization of heart transplantation as an end stage therapy for cardiomyopathy improves survival.

8. Wilkinson, Orav EJ, **Lipshultz SE**, et al. Race/ethnic disparities in outcomes for children with cardiomyopathy.
9. **Lipshultz SE**, Alvarez et al. Serial echocardiography in children with cardiomyopathy.
10. Rusconi P, **Lipshultz SE**, et al. Outcomes and predictors of children with familial dilated cardiomyopathy.
11. Towbin J, **Lipshultz SE**, et al. Genetic and viral findings in pediatric cardiomyopathy.
12. **Lipshultz SE**, PCMR Investigators, et al. Cohort study findings.
13. Messiah S, Miller T, **Lipshultz S**, Bandstra E. Toddler and preschool adiposity and rebound years related to growth in infancy in cocaine-exposed children.
14. Messiah S, Miller T, **Lipshultz S**, Bandstra E. Teenaged post-puberty and rebound years related to growth in infancy in cocaine-exposed children

Editor of Books

1. **Lipshultz SE**. (Editor). Cardiology in AIDS. New York: Chapman and Hall. Later published by Oxford University Press. 513 pages. Hardcover book. (1998). ISBN-10: 0-412-08861-4. ISBN-13: 9780412088612. NLM: WC 503.5 C267. LCCN: 97-42609. LC: RC669 C274. 30 multi-authored chapters.
2. Ippolito G, Petrosillo N, Barbaro G, **Lipshultz SE**. HIV-Associated Cardiovascular Disease. Clinical and Biological Insights. New York: Annals of The New York Academy of Sciences. (2001). ISBN: 1-57331-354-8 (cloth) and 1-57331-355-6 (paper). 23 Multi-authored Chapters.
3. **Lipshultz SE**, others. Handbook on Pediatric Cardiology. Singapore: World Scientific Publishing/Imperial College Press. Invited and under negotiation. 2008.
4. **Lipshultz SE**, others. Cardiac Oncology. London: Springer UK. (Grant Weston, Senior Editor – in development to be commissioned) (4/8/2009 suggested by Springer in writing, 10/8/09 proposal completed).
5. **Lipshultz SE**, others. Pediatric Cardiomyopathy. London: Springer UK. (Grant Weston, Senior Editor – in development to be commissioned) (under negotiation - 2011).
6. **Lipshultz SE**, Miller TL, Messiah SE. Pediatric Metabolic Syndrome : Comprehensive Clinical Review and Related Health Issues. London: Springer Verlag London Ltd acting in cooperation with Springer-Verlag GmbH Berlin Heidelberg, Springer Science and Business Media LLC New York and Springer Japan KK. (Grant Weston, Senior Editor – commissioned) (3/15/2010 suggested by Springer in writing, 3/25/10 proposal completed, 5/15/10-Springer accepted and sent contract) (Fully executed and scheduled for publication in September 2011, 11/13 chapters with Springer-6/11).
7. Barach P, Jacobs J, **Lipshultz SE**. Outcomes Analysis, Quality Improvement, and Patient Safety for Pediatric and Congenital Cardiac Disease: Theory, Implementation and Applications. London: Springer Verlag London Ltd acting in cooperation with Springer-Verlag GmbH Berlin Heidelberg, Springer Science and Business Media LLC New York and Springer Japan KK. (Grant Weston, Senior Editor – commissioned for publication 7/5/11) (Scheduled for publication in June 2012).

Book Section Editor

1. **Lipshultz SE**. Seven Cardiology Chapters. In Primary Pediatric Care, Fourth Edition (ed. Hoekelman RA, Friedman SB, Nelson NM, Seidel HM, Weitzman ML). St Louis: Mosby (2000).

Guest Journal Editor

1. **Lipshultz SE.** Cardiovascular Complications of Cancer Treatment in Children – Part I. Progress in Pediatric Cardiology. 8 (2):49-96 (1997).
2. **Lipshultz SE.** Cardiovascular Complications of Cancer Treatment in Children – Part II. Progress in Pediatric Cardiology. 8 (3):97-164 (1998).
3. Auslender M, **Lipshultz SE,** Artman M. Pediatric Heart Failure: Part I Pathophysiology. Progress in Pediatric Cardiology. 11:175-254 (2000).
4. Auslender M, Artman M, **Lipshultz SE.** Pediatric Heart Failure: Part II Pharmacologic Management. Progress in Pediatric Cardiology. 12:1-154 (2001).
5. Ippolito G, Petrosillo N, Barbaro G, **Lipshultz SE.** HIV-Associated Cardiovascular Disease: Clinical and Biological Insights. Ann NY Acad Sci. 946:1-326 (A 21 article book-also listed above as a book) (November 2001).
6. **Lipshultz SE,** Vermilion RP, Alfieris G. Optimal Delivery of Care for Pediatric Cardiovascular Disease: Part I. Progress in Pediatric Cardiology 18:1-104 (2003).
7. **Lipshultz SE,** Vermilion RP, Alfieris G. Optimal Delivery of Care for Pediatric Cardiovascular Disease: Part II. Progress in Pediatric Cardiology 18:105-180 (2003).
8. **Lipshultz SE,** Vermilion RP, Alfieris G. Optimal Delivery of Care for Pediatric Cardiovascular Disease: Part III. Progress in Pediatric Cardiology 20:1-100 (2005).
9. **Lipshultz SE (Guest Editor).** Anthracycline-Induced Cardiotoxicity in Cancer Patients: The Scope of the Problem. Seminars in Oncology 33(3, suppl 8):S1-S27 (2006).
10. **Lipshultz SE,** Colan SD, Towbin JA, Wilkinson JD. Idiopathic and Primary Cardiomyopathy in Children: Part I. Progress in Pediatric Cardiology 23(1-2): 1-102 (September 2007).
11. **Lipshultz SE,** Colan SD, Towbin JA, Wilkinson JD. Idiopathic and Primary Cardiomyopathy in Children: Part II. Progress in Pediatric Cardiology 24(1): 1-86 (November 2007).
12. **Lipshultz SE,** Colan SD, Towbin JA, Wilkinson JD. Idiopathic and Primary Cardiomyopathy in Children: Part III. Progress in Pediatric Cardiology 25(1): 1-116 (April 2008).
13. **Lipshultz SE,** Barach PR, Jacobs JP, Laussen PC. The Future of Pediatric Cardiac Care. Progress in Pediatric Cardiology. (18 articles) (November 2011).
14. **Lipshultz SE.** Pediatric Cardiomyopathy. Current Cardiology Reviews. (Invited 9/30/09 to Guest Edit an issue of this journal) (2009).
15. **Lipshultz SE,** Wilkinson JD, Colan SD, Towbin JA. Cardiomyopathy in Children: Part I. Progress in Pediatric Cardiology 31(1): 1-72 (ISSN 1058-9813) (January 2011).
16. **Lipshultz SE,** Wilkinson JD, Colan SD, Towbin JA. Cardiomyopathy in Children: Part II. Progress in Pediatric Cardiology 31(2): 73-142 (May 2011).
17. **Lipshultz SE,** Wilkinson JD, Colan SD, Towbin JA. Cardiomyopathy in Children: Part III. Progress in Pediatric Cardiology (August 2011).

Book Chapters:

1. **Lipshultz SE.** Colan SD. The use of echocardiography and Holter monitoring in the assessment of anthracycline-treated patients. In Long term complications of treatment of children and adolescents for cancer. (ed. Bricker JT, Green DM, D'Angio, GJ). New York: Wiley-Liss pages 45-62 (1993).
2. **Lipshultz SE.** Cardiovascular manifestations of pediatric HIV infection. In Pediatric AIDS. The challenge of HIV infection in infants, children, and adolescents, Second Edition (ed. Pizzo PA, Wilfert CM). Baltimore: Williams & Wilkins pages 483-511 (1994).
3. **Lipshultz SE,** Bancroft E, Boller AM. Human immunodeficiency virus in childhood. In The Science and Practice of Pediatric Cardiology, Second Edition (eds. Garson A, Bricker JT, Fisher DJ, Neish SR). Philadelphia: Lea and Febiger, pages 1823-1850 (1998)

4. Boller AM, Al-Attar I, Orav EJ, **Lipshultz SE**. Cardiovascular morbidity and mortality in pediatric HIV. In *Cardiology in AIDS*. (ed. Lipshultz SE). New York: Chapman and Hall, pages 77-97 (1998).
5. Grenier MA, **Lipshultz SE**. Left ventricular hypertrophy in HIV Disease. In *Cardiovascular manifestations of HIV infection*. (ed. Lipshultz SE). New York: Chapman and Hall, pages 111-140 (1998).
6. **Lipshultz SE**, Colan SD, Grenier MA. Left ventricular dysfunction in HIV-infected infants and children. In *Cardiology in AIDS*. (ed. Lipshultz SE). New York: Chapman and Hall pages 141-153 (1998).
7. Wong J, **Lipshultz SE**. Cardiovascular complications of pharmacotherapeutic agents (excluding the antiretrovirals) in pediatric HIV infection. In *Cardiology in AIDS*. (ed. Lipshultz SE). New York: Chapman and Hall, pages 331-344 (1998).
8. Moorthy LN, **Lipshultz SE**. Cardiovascular monitoring of HIV-infected patients. In *Cardiology in AIDS*. (ed. Lipshultz SE). New York: Chapman and Hall, pages 345-386 (1998).
9. Giantris A, **Lipshultz SE**. Cardiac therapeutics in HIV-infected patients. In *Cardiology in AIDS*. (ed. Lipshultz SE). New York: Chapman and Hall pages 387-422 (1998).
10. **Lipshultz SE**, Bancroft EA, Boller AM. Cardiovascular manifestation of HIV infection in children. In *Pediatric AIDS. The challenge of HIV infection in infants, children, and adolescents, Third Edition* (ed. Pizzo PA, Wilfert CM) Philadelphia: Lippincott Williams & Wilkins pages 335-361 (1998).
11. Hoffman M, **Lipshultz SE**, Miller TL. Malnutrition and cardiac abnormalities in the HIV-infected patient. In *Nutritional Aspects of HIV Infection*. (eds. Miller TL, Gorbach S). London: Arnold. Pages 133-139 (1999).
12. Giantris A, **Lipshultz SE**. Cardiac Disease. In *AIDS Therapy*. (ed. Dolin R, Masur H, Saag MS). New York: Churchill Livingstone, Inc. pages 680-698 (1999).
13. Grenier MA, **Lipshultz SE**. Cardiac Problems. In *Handbook of Pediatric HIV Care*, (ed. Zeichner SL, Read JS). Philadelphia: Lippincott Williams & Wilkins pages 376-384 (1999).
14. Fisher SD, **Lipshultz SE**. AIDS and the Cardiovascular System. In *Heart Disease, Sixth Edition* (ed. Braunwald E, Zipes DP, Libby P). Philadelphia: W.B. Saunders Co. pgs 2211-2222 (2001).
15. Fisher SD, **Lipshultz SE**. AIDS and the Cardiovascular System. In *Harrison's Internal Medicine Online*. (ed. Braunwald E) (2001).
16. Adams MJ, Constine L, **Lipshultz SE**. Radiation Effects on the Heart. In *Cardiology*. (ed. Crawford MH, DiMarco JP). London: Mosby International (2001) 8.15.1-8.
17. **Lipshultz SE**. Congestive Heart Failure. In *Primary Pediatric Care, Fourth Edition* (ed. Hoekelman RA, Adams HM, Nelson NM, Weitzman ML, Wilson MH). St Louis: Mosby pages 1975-1979 (2001).
18. Starc TJ, McGrath KM, **Lipshultz SE**. Preventive Cardiology. In *Primary Pediatric Care, Fourth Edition* (ed. Hoekelman RA, Adams HM, Nelson NM, Weitzman ML, Wilson MH). St Louis: Mosby pages 311-317 (2001).
19. Buzzard C, **Lipshultz SE**. Hypertension. In *Primary Pediatric Care, Fourth Edition* (ed. Hoekelman RA, Adams HM, Nelson NM, Weitzman ML, Wilson MH). St Louis: Mosby pages 1142-1149 (2001).
20. Harmon WG, **Lipshultz SE**. Kawasaki's Syndrome. In *Gellis & Kagan's Current Pediatric Therapy 17/e* (0-7216-8871-3) (ed. Burg FD, Ingelfinger JR, Polin RA, Gershon AA). Philadelphia: W.B. Saunders Co. pages 550-553 (2001)

21. Herman E, **Lipshultz SE**, Ferrans VJ. The use of cardiac biomarkers to detect myocardial damage induced by chemotherapeutic agents. In Wu AHB, editor. *Cardiac Markers*. 2nd ed. Totowa, NJ: Humana Press. pp. 87-110 (2003).
22. Keesler MJ, Fisher SD, **Lipshultz SE**. Abnormal Cardiovascular Function in HIV-Infected Infants and Children (Chapter 17). In *Medical Management of AIDS in Children*, (ed. Shearer WT, Hanson IC). Philadelphia: W.B. Saunders Co. (ISBN 0-7216-8284-7) pages 303-320 (2003).
23. Fisher SD, **Lipshultz SE**. Cardiac Disease. Chapter 59. In *AIDS Therapy* 2nd ed. (ed. Dolin R, Masur H, Saag MS). New York: Churchill Livingstone (Elsevier Science). Pgs 814-826 (2003).
24. Hinkle AS, Proukou CB, Deshpande SS, Duffy SA, Kozlowski AM, French CA, **Lipshultz SE**. Chapter 4a. Cardiotoxicity caused by chemotherapy. In *Late Effects of Childhood Cancer* (ed. Wallace WHB, Green DM). London: Edward Arnold. Pages 85-100 (2004) (ISBN: 0-340-80803-9). This contribution favorably reviewed by Pui C-H. Book Review: *Late Effects of Childhood Cancer*. *N Engl J Med* 2005;352(4):425.
25. Adams MJ, Constine LS, **Lipshultz SE**. Radiation. In: Crawford MH, DiMarco JP, Paulus WJ, editors. *Cardiology, Second Edition*. Edinburgh, UK: Mosby; pages 1583-1590 (2004).
26. Dadlani GH, **Lipshultz SE**. Chapter 30. Cardiac Problems. In *Textbook of Pediatric HIV Care*. (ed. Zeichner SL, Reid JS). London: Cambridge Univ Press. ISBN-10: 0521821533. Pages 468-478 (2005).
27. Fisher SD, **Lipshultz SE**. Cardiovascular Abnormalities in HIV-Infected Individuals. In *Braunwald's Heart Disease. A Textbook of Cardiovascular Medicine, Seventh Edition* (ed. Zipes DP, Libby P, Bonow RO, Braunwald E). Philadelphia: Elsevier Saunders. Pgs 1719-1730 (2005).
28. Tisma-Dupanovic S, Harmon WG, Adams MJ, Dadlani GH, Kozlowski A, Duffy S, Harbowy L, Zareba K, French C, McLaughlin K, **Lipshultz SE**. Cancer Therapy-Related Cardiotoxicities. In *Pediatric Heart Failure* (ed. Shaddy RE, Wernovsky G). Boca Raton: Taylor & Francis. Pages 665-738 (2005).
29. Dadlani GH, **Lipshultz SE**. Chapter 30: Cardiac Problems. In *Handbook of Pediatric HIV Care, Second Edition* (ed. Zeichner SL, Reid JS). London: Cambridge Univ Press. ISBN-10 0-521-52906-9. Pages 554-566 (2006).
30. Dadlani GH, Harmon WG, **Lipshultz SE**. Chapter 18. Dilated Cardiomyopathy. In *Heart Failure in Children and Young Adults: From Molecular Mechanisms to Medical and Surgical Strategies*. (ed. Chang AC, Towbin JA). New York: Elsevier-Saunders. Pages 248-263 (2006).
31. Fisher SD, **Lipshultz SE**. Cardiovascular Manifestations of HIV Infection Children. In *The Science and Practice of Pediatric Cardiology, Third Edition* (ed. Bricker JT, Garson A Jr, Fisher DJ, Neish SR, Friedman R, Geva T, Towbin JA). Phila: Lippincott Williams & Wilkins. (2005).
32. Adams MJ, Duffy SA, Constine LS, **Lipshultz SE**. Cardiovascular Effects of Cancer Therapy. In *Survivors of Childhood and Adolescent Cancer*. (ed. Schwartz CL, Hobbie WL, Constine LS, Ruccione KS). Chapter 10. Berlin-Heidelberg: Springer-Verlag. Pages 133-159 (2005).
33. Newburger JW, Harmon WG, **Lipshultz SE**. Kawasaki Disease. In *Current Pediatric Therapy 18th Edition* (ISBN-10: 0-7216-0549-4) (ed. Burg FD, Ingelfinger JR, Polin RA, Gershon AA). Philadelphia: Saunders Elsevier pages 497-503 (2006).
34. Sharma TS, **Lipshultz SE**. Chapter 33. Cardiac Complications. (Three sub-chapters: 33.1 Cardiomyopathy; 33.2 Pericarditis; 33.3 Cardiovascular Disease). *American Academy of HIV Medicine Fundamentals of HIV Medicine*. (ed. Stansell J, Moore M) (http://aahivm.org/CME_EXAM/study_guide_payment.html) pp. 591(2007).
35. Adams MJ, Prosnitz RG, Constine LS, Marks LB, **Lipshultz SE**. Radiation biophysiology: Chapter 7: Screening for cardiovascular disease in survivors of thoracic radiation. In: Rubin P,

- Constine LS, Marks LB, Okunieff P (eds). *Late Effects of Cancer Treatment on Normal Tissues* (Medical Radiology – Diagnostic Imaging and Radiation Oncology series) (ISBN: 978-3-540-49069-2, ISSN: 0942-5373, DOI: 10.1007/978-3-540-49070-8_7). Berlin, Heidelberg, New York: Springer. pp 47-60 (2007).
36. **Lipshultz SE.** Drug Cardiotoxicity Research in Children. *Drug Toxicity Research Trends* (ed. Columbus F). Hauppauge, NY: Nova Science Publishers, Inc. (Invited) (2007).
 37. Alvarez JA, Miller TL, Starc TJ, McGrath K, **Lipshultz SE.** Chapter 32 - “Preventive Cardiology”. In *American Academy of Pediatrics Textbook of Pediatric Care*, (eds. McInerny TK, Adams HM, Campbell DE, Kamat DM, Kelleher KJ). Oak Grove Village, IL: American Academy of Pediatrics (pages 1-15, 2935 pp.) (ISBN-10: 1581102682 EAN: 9781581102680) (11/15/2008).
 38. Sokol KC, Messiah SE, Buzzard CJ, **Lipshultz SE.** Chapter 191 – “High Blood Pressure in Infants, Children, and Adolescents. In *American Academy of Pediatrics Textbook of Pediatric Care*, (eds. McInerny TK, Adams HM, Campbell DE, Kamat DM, Kelleher KJ). Oak Grove Village, IL: American Academy of Pediatrics (in press – pages 1-15) (ISBN-10: 1581102682 EAN: 9781581102680) (11/15/2008).
 39. Sharma TS, Perez LM, Miller TL, **Lipshultz SE.** Chapter 349 – “Heart Failure”. In *American Academy of Pediatrics Textbook of Pediatric Care*, (eds. McInerny TK, Adams HM, Campbell DE, Kamat DM, Kelleher KJ). Oak Grove Village, IL: American Academy of Pediatrics (in press – pages 1-9) (ISBN-10: 1581102682 EAN: 9781581102680) (11/15/2008).
 40. **Lipshultz SE,** Rusconi P, Scully RE. Chapter 18: Assessment of cardiotoxicity during anti-cancer therapy. In: *NT-proBNP as a Biomarker in Cardiovascular Diseases*. (eds. Bayes-Genis A and Januzzi JL, Jr.). Barcelona: Prous Science S.A. and Thompson Reuters (Invited for English, and potentially Spanish and Japanese editions – accepted November 2007) pp. 183-198 (2008).
 41. **Lipshultz SE,** Sanchez J, Carrillo A, Preble S, Scully RE. Cardiac effects of growth hormone treatment in pediatric populations. In: Berhardt LV, ed. *Advances in Medicine and Biology*. Volume 1. Hauppauge, New York: Nova Science Publishers. (Hardcover, Pub Date: 2nd Quarter 2010, ISBN: 978-1-60876-863-9) (2010).
 42. Fisher SD, **Lipshultz SE.** Chapter 67: Cardiovascular abnormalities in HIV-infected individuals. In: *Braunwald’s Heart Disease. A Textbook of Cardiovascular Medicine, Eighth Edition* (eds. Libby P, Bonow RO, Mann DL, Zipes DP, Braunwald E). Philadelphia: Elsevier Saunders. pp. 1793-1814 (2008).
 43. Scully R, **Lipshultz SE.** Chapter 4: Cardiovascular toxicity of antitumor drugs: Dimensions of the problem in children. In: *Cardiotoxicity of Non-Cardiovascular Drugs* (ed. Minotti G). London: John Wiley & Sons, Ltd. (ISBN-10: 0-470-77274-3, ISBN-13: 978-0-470-77274-4) pp. 97-126. (April 2010).
 44. Scully R, Miller A, Grant Y, **Lipshultz SE.** Section III: Chapter 6.22: Mechanisms of drug-induced cardiovascular toxicology: anthracycline, herceptin and CV toxicity (Manuscript number 726). In: *Comprehensive Toxicology 2nd Edition, Volume 6 of the Comprehensive Toxicology Series* (ed. McQueen CA, Section Editor: Walker MK). Oxford: Elsevier. pp. 413-427. ISBN: 9780080468686(2010).
 45. Mustian KM, Adams MJ, Schwartz RG, **Lipshultz SE,** Constine LS. Cardiotoxic effects of radiation therapy in Hodgkin’s lymphoma and breast cancer survivors and the potential mitigating effects of exercise. In: *CURED II • LENT Cancer Survivorship Research and Education – Late Effects on Normal Tissues*. (eds. Rubin P, Constine LS, Marks LB, Okunieff P). Part of the series entitled “Medical Radiology-Radiation Oncology” with eds. Brady LW, Heilmann H-P, Molls M, Nieder C. Berlin Heidelberg: Springer-Verlag. pp. 103-116 (2008). ISBN: 978-3-540-76270-6

46. Fisher SD, **Lipshultz SE**. Chapter 72: Cardiovascular abnormalities in HIV-infected individuals. In: Braunwald's Heart Disease. A Textbook of Cardiovascular Medicine, Ninth Edition and electronic edition (eds. Bonow RO, Mann DL, Zipes DP, Libby P). Philadelphia: Elsevier Saunders. Pages 1618-27. ISBN: 978-1-4377-0398-6. (2011).
47. Adams MJ, Constine LS, **Lipshultz SE**. Section 8: Secondary Heart Disease: Cardiac Responses to Environmental Stress. Chapter 140: Radiation-induced Heart Disease. In: Crawford MH, DiMarco JP, Paulus WJ, editors. Cardiology, Third Edition. Philadelphia: Mosby-Elsevier; pages 1833-2841. (2000 pp. ISBN:978-0-7234-3485-6) (2010).
48. Landy DC, Miller TL, Wilkinson JD, **Lipshultz SE**. Section II: Cardiotoxicity of Anti-cancer Treatment. Chapter 8. Cardiac considerations in the treatment of cancer in infants and children. In: Cancer and the Heart, Second Edition (eds. Ewer MS and Yeh ETH). People's Medical Publishing House – USA (PMPH-USA). (Accepted for publication-5/2010-in press)(2010).
49. Messiah SA, Arheart KL, **Lipshultz SE**, Miller TL. Prevalence of the metabolic syndrome in US youth. Global Perspectives on Childhood Obesity: Current status, consequences and prevention. (ed. Bagchi D) Elsevier. Academic Press (ISBN-13: 978-0-12-374995-6, ISBN: 0123749956) 538 pages. (15-20 printed pages@540 words/page/June-July 2010 publication date, copyright 2011) (submitted to the journal/editor 1/10/10, galley proofs reviewed 6/2010).
50. Alvarez JA, Miller TL, Messiah SE, **Lipshultz SE**. Chapter 32 - "Lipid Abnormalities". In American Academy of Pediatrics Textbook of Pediatric Care, (eds. McInerny TK, Adams HM, Campbell DE, Kamat DM, Kelleher KJ). Oak Grove Village, IL: American Academy of Pediatrics, 2nd Ed. Accepted – In Press.
51. Chandar J, Zilleruelo G, Messiah SE, **Lipshultz SE**. Chapter 157 – "High Blood Pressure." In American Academy of Pediatrics Textbook of Pediatric Care, (eds. McInerny TK, Adams HM, Campbell DE, Kamat DM, Kelleher KJ). Oak Grove Village, IL: American Academy of Pediatrics, 2nd Ed. Accepted – In Press.
52. Harmon W, Rusconi P, Miller TL, **Lipshultz SE**. Chapter 351 – "Heart Failure". In American Academy of Pediatrics Textbook of Pediatric Care, (eds. McInerny TK, Adams HM, Campbell DE, Kamat DM, Kelleher KJ). Oak Grove Village, IL: American Academy of Pediatrics, 2nd Ed. Accepted – In Press.
53. Qureshi MY, Wilkinson JD, **Lipshultz SE**. Chapter 9. The relationship of childhood obesity with cardiomyopathy and heart failure. In (eds. **Lipshultz SE**, Miller TL, Messiah SE.) Pediatric Metabolic Syndrome: Comprehensive Clinical Review and Related Health Issues. London: Springer Verlag London Ltd acting in cooperation with Springer-Verlag GmbH Berlin Heidelberg, Spring Science and Business Media LLC New York and Springer Japan KK. Accepted – In press.
54. Brown SR, **Lipshultz SE**. Chapter 10. Childhood metabolic syndrome and cancer risk. In (eds. **Lipshultz SE**, Miller TL, Messiah SE.) Pediatric Metabolic Syndrome: Comprehensive Clinical Review and Related Health Issues. London: Springer Verlag London Ltd acting in cooperation with Springer-Verlag GmbH Berlin Heidelberg, Spring Science and Business Media LLC New York and Springer Japan KK. Accepted – In press.
55. Doshi N, Chang A, **Lipshultz SE**. Cardiovascular Late Effects. In (ed. Torno L). Handbook of Pediatric Cancer Survivorship. (2011).
56. Ewer MS, **Lipshultz SE**. Cardiovascular consequences in adult survivors of childhood cancer. In: Braunwald's Heart Disease. A Textbook of Cardiovascular Medicine Update, Ninth Edition and electronic edition (eds. Bonow RO, Mann DL, Zipes DP, Libby P). Philadelphia: Elsevier Saunders. (2011).

53. Qureshi MY, Messiah S, Miller TL, **Lipshultz SE**. Atherosclerosis. In (eds. **Lipshultz SE**, Miller TL, Messiah SE.) Pediatric Metabolic Syndrome: Comprehensive Clinical Review and Related Health Issues. London: Springer Verlag London Ltd acting in cooperation with Springer-Verlag GmbH Berlin Heidelberg, Springer Science and Business Media LLC New York and Springer Japan KK. Accepted – In press.

Book Reviews:

1. **Lipshultz SE**. Viral infections of the heart. N Engl J Med 1994;330:1323.

Abstracts: (294 abstracts with 87 from 2008-2010, * = platform presentation-211, ** = poster presentation-83)

CONTINUING MEDICAL EDUCATION ACTIVITY COORDINATION:

1. Editor and CME Course Director. Lysosomal Storage Diseases: Current Status, Hope for the Future. A Continuing Education Publication. R&R Healthcare Communications, Inc. and Genzyme Pharmaceuticals. Sponsored by University of Rochester School of Medicine and Dentistry Continuing Medical Education Office. (2003).
2. Organizing Committee Member, Masters of Pediatrics CME Course. University of Miami School of Medicine. (2003-current).
3. Writing Committee Member, American Heart Association Patient Information Document on Cardiomyopathy in Children. Web Site and Printed Booklets. (2004-2005).
4. Organizing Committee Member, Pediatric Nephrology Seminars CME Course. University of Miami School of Medicine (2004-current).
5. Dr. Lipshultz is featured in the educational DVD that serves as an easy-to-understand overview for parents of children with cardiomyopathy. This 38-minute video is called "Secrets of the Heart: Living with Pediatric Cardiomyopathy." This was produced by the Children's Cardiomyopathy Foundation and presents the unique stories of three very different families, all who have successfully lived through the challenges associated with cardiomyopathy. Topics covered include: 1. Types and cases of pediatric cardiomyopathy, 2. Diagnosis & causes, 3. Treatment options, 4. Coping with the disease, 5. Daily life with cardiomyopathy, and 6. Advances in research & treatment (2005).
6. Director, University of Miami Initiative to Improve Child Health in Ukraine -- Exchange program where in January 2006 six leading pediatricians from Ukraine spent a week at the University of Miami for pediatric education. This is a formal program funded by the Government of Ukraine, the United States Congress, and the Children of Chernobyl Relief and Development Fund. There have been teaching conferences and consulting on child health by Dr. Lipshultz.
7. Organizer and Chair of the Conference. NHLBI and Children's Cardiomyopathy Foundation First International Pediatric Cardiomyopathy Scientific Workshop: Conference on Idiopathic and Primary Cardiomyopathy in Children: Research Directions and Strategies. Bethesda, MD. January 25-26, 2007. The presentations from the conference are available online. The proceedings have been published in Progress in Pediatric Cardiology in three volumes. The first was Volume 23, Issues 1-2, September 2007 (pages 1-102). The second was Volume 24, Issue 1, November 2007 (pages 1-86). The third was Volume 24, Issues 2-3, December 2007 (pages 1-130).

8. Lecturer and Course Director. Course Title: "Fetal Origins of Adult Cardiovascular Disease." NICUniversity, an educational resource for the neonatology community (Free CE/CME & Educational Resources for the Neonatal Care Professional). Date released: 3/26/08.
9. Organizer and Chair of the Conference. NHLBI and Children's Cardiomyopathy Foundation Second International Pediatric Cardiomyopathy Scientific Workshop: Conference on Idiopathic and Primary Cardiomyopathy in Children: Research Directions and Strategies. Bethesda, MD. May 12-14, 2010. The presentations from the conference are available online (<http://www.childrenscardiomyopathy.org>). The proceedings will be published in Progress in Pediatric Cardiology in three volumes.

TEACHING EXPERIENCE:

National/International Invited Lectures (2005-2010, Selected)

1. Invited Plenary Speaker, Session Moderator, and Meet the Professors Leader "Late cardiotoxicity in long-term survivors of childhood cancer." The Masters of Pediatrics Program. Miami Beach, FL (2005).
2. Invited Plenary Speaker and Moderator, "Cardiotoxic Effects of Cancer Therapy in Children." In the Pediatric and Adolescent Cancers Special Interest Panel Sessions. Annual meeting of the Joint Cancer Conference of the Florida Universities, Orlando, FL (2005).
3. Invited Plenary Speaker, "Cardiac troponin T as an early marker for cardiotoxicity" and Roundtable Speaker. Anthracycline cardiotoxicity: New leads to an old mystery symposium. XXV International Congress of Physiological Sciences. San Diego, CA (2005).
4. Invited Plenary Speaker and Session Chairman, "Heart Failure in AIDS: a sleeping giant?" and "The possible role of cytokines." Heart Failure 2005 - International Congress on Heart Failure. Lisbon, Portugal (2005).
5. Invited Plenary Speaker, "The Pediatric Cardiomyopathy Registry." NIH Special Emphasis Panel Working Group on Cardiomyopathies of Rare Diseases. NHLBI Division of Heart and Vascular Diseases and the NIH Office of Rare Diseases, Bethesda, MD. (2005).
6. Invited Plenary Speaker, "Cardiovascular Issues in Pediatric Chronic Kidney Failure." 30th International Symposium on Pediatric Nephrology. Miami Beach, FL (2005).
7. Invited Plenary Speaker. CCURED 1 Meeting. Cancer Survivor Research and Education Committee (CURED) of RTOG. (2005).
8. Invited Participant. NCI and Lance Armstrong Foundation Small Grants Program for Behavioral Research in Cancer Control Grantee Meeting. Bethesda, MD (2005).
9. Invited Plenary Speaker, "Fetal Origins of Adult Cardiovascular Disease." 32nd Annual International Symposium on Neonatology. University of Miami. Key Biscayne, FL (2005).
10. Invited Plenary Speaker, "Congestive Heart Failure in Pediatrics." Pediatric Multi-Specialty Review Conference. Baptist Children's Hospital, Miami, FL (2005).
11. Invited Plenary Speaker, "HAART-Associated Cardiovascular Toxicity". Clinical Research Forums in Pediatrics. Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL (2005).
12. Invited Speaker. "Baseline Predictors of Pediatric Cardiomyopathy Outcomes. International Society of Heart and Lung Transplantation – Pediatric Heart Transplant Study Meeting. Philadelphia, PA (2005).
13. Invited Speaker. "Cardiac Studies" NCI DFCI ALL Investigators' Meeting and Field Coordinators' Meeting. Boston, MA (2005).
14. Invited Plenary Speaker. "Anthracycline Cardiotoxicity." Lovelace Respiratory Research Institute, Albuquerque, NM (2005).

15. Invited Plenary Speaker, "Cardiovascular status of HAART-exposed infants and children." 9th International Conference on Environmental Mutagens (9th ICEM) and the 36th Annual Meeting of the Environmental Mutagen Society (EMS). Symposium titled "Transplacental Exposure to Nucleoside Analogs: Mitochondrial Damage and Fetal Health, San Francisco, CA (2005).
16. Invited Speaker, "Cardiotoxic Late Effects in Long-Term Survivors of Childhood Cancer." Alumni Symposium, Rainbow Babies and Children's Hospital, Case Western Reserve University School of Medicine, Cleveland, OH (2005).
17. Invited Plenary Speaker, "Cardiovascular Status of HAART-Exposed Infants and Children." Highly-Active Antiretroviral Therapy Grantees Meeting, National Heart, Lung, and Blood Institute, Bethesda, MD (2005).
18. Invited Grand Rounds Speaker, "Late Cardiotoxicity in Survivors of Childhood Cancer." Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL (2005).
19. Invited Plenary Speaker. "Cardiovascular Status of HAART-Exposed Infants and Children." NIH Women and Infants' Transmission Study Executive Committee Meeting. Bethesda, MD (2005).
20. Organizer and Speaker. Annual Meeting of the Pediatric Cardiomyopathy Registry. American Heart Association Annual Session, Dallas, TX (2005).
21. Invited Speaker. "Pediatric Oncology – Active Issues". Stop Children's Cancer Now! Non-profit Foundation Meeting. Palm Beach, FL (2005).
22. Invited Speaker. "Cardiac Studies in HIV". Scientific Oversight Committee. NIH Pediatric HIV/AIDS Cohort Study (PHACS). Bethesda, MD (2005).
23. Invited Speaker. Miami Dade County Public Health Trust Board of Trustees Meeting. Miami, FL (2005).
24. Invited Plenary Speaker. "Cardiac Late Effects of Non-Therapeutic Radiation Exposure." Radiation and Non-cancer Diseases, Cardiovascular Disease International Conference. Radiation Effects Research Foundation – A Cooperative Japan-United States Research Organization. Hiroshima, Japan (2006).
25. Invited Plenary Speaker. "Neonatal Origin of Childhood and Adult Hypertension." XXXIII Pediatric Nephrology Seminar. Miami Beach, FL (2006).
26. 1. Co-Chair of Session 1: "Clinical Aspects"; 2. Invited Plenary Speaker. "Clinical experience with dexrazoxane"; and 3. Discussion Leader "Risk: benefit ratio of cardioprotectants." Menarini Foundation (Fondazione Internazionale Menarini) International Workshop on Anthracycline Cardiotoxicity: Molecular Mechanisms and Clinical Correlates. Como, Italy (2006).
27. Invited Plenary Speaker and Conference Organizer. First International Conference on Cardiac Issues in Cancer. Houston, TX (2006).
28. Invited Workshop Speaker and Workshop Organizer. Workshop entitled: "Pediatric Cardiology Update 2006". Talk entitled: "Congestive Heart Failure in Fetuses, Neonates, Infants, Children, and Adolescents. The Masters of Pediatrics Scientific Symposium. Bal Harbour, FL (2006).
29. Invited Speaker. NCI Dana Farber Cancer Institute Childhood ALL Consortium Investigator Meeting. Cardiac Oncology Studies Update. Boston, MA (2006).
30. Invited Plenary Speaker. "Cardiovascular Late Effects in Long-Term Survivors of Childhood Cancer." 11th World Congress on Advances in Oncology and 9th International Symposium on Molecular Medicine. Crete, Greece (2006).
31. Invited Plenary Speaker. "Ukrainian Pediatric Health Care" Government of Ukraine Presidential Conference "Partnerships for Health". Kyiv, Ukraine (March 2006).
32. Invited Plenary Speaker. "Late Cardiovascular Effects of Mediastinal Irradiation for Childhood Cancer." International Conference entitled "Twenty Years after Chernobyl: A Vision for the Future." Government of Ukraine, International Atomic Energy Agency, Kyiv, Ukraine (April 2006).

33. Invited Plenary Speaker. "The cardiovascular health of children and adults following Chernobyl and Hiroshima." International Conference entitled "Rebirth, Renewal and Human Development: A Humanitarian Forum – Chernobyl 20th Anniversary." Government of Ukraine, Ukraine 3000, UNESCO, Children of Chernobyl Relief and Development Fund. Kyiv, Ukraine (April 2006). In the coverage in the Chernobyl Chronicle it stated "Dr. Lipshultz warned that in addition to the thyroid cancer epidemic and the increase in various oncological diseases, the world must remain vigilant for heart diseases, as children exposed to chemotherapy and atomic bomb tests have an eight-fold higher incidence of cardiomyopathy and are vulnerable to sudden death from heart attack and other cardiac illnesses." The conference was attended by the First Lady of Ukraine.
34. First Ross Visiting Professorship in Pediatrics, Department of Pediatrics, New York University Medical Center, New York University School of Medicine-Bellevue Hospital Center, New York. Pediatric Grand Rounds Speaker "Late cardiovascular abnormalities in long-term survivors of childhood cancer" (March 2007).
35. Invited Plenary Speaker. "Potential treatments of radiation-induced cardiovascular disease." Symposium entitled: "Health effects from low-level radiation." International Atomic Energy Agency, Vienna, Austria. (June 2006).
36. Invited Plenary Speaker. "Pathophysiology of Anthracycline Chemotherapy and Radiation Associated Cardiomyopathies." Cancer and Cardiovascular Disease: Increasing the Success of Chemotherapy by Reducing CVD as a Barrier and Long-term Risk. CONQUER (Cardiology Oncology InterNational Quest to Educate and Research Heart Failure) Committee. M.D. Anderson Cancer Center and University of Texas Medical Branch. Houston, TX (October 2006).
37. Invited Speaker. "1. Welcome/Introduction and 2. Closing Remarks". "Pediatric Bone Marrow Transplant Treatment Paradigms, The New Era and Beyond." CME University of Miami Miller School of Medicine. Miami, FL (June 2006).
38. Session Chair and Invited Plenary Speaker. Dr. Lipshultz was honored as the Keynote Address Speaker at this international meeting. "Cardioprotection During Pediatric Cancer Treatment." International Review Symposium entitled: "Cancer Therapy Improvement by Toxicity Reduction and Cardioprotection." (Coordinators: Kurt Hellmann DM and Rudolf Steiner MD). Royal Society of Medicine. London, England (October 2006).
39. Invited Plenary Speaker. Several Talks. 1. "The diagnosis, treatment, and outcome of congestive heart failure from fetus to adolescent." 2. "Latest update on dilated cardiomyopathy and hypertrophic cardiomyopathy during childhood." 3. "Improving congenital heart surgical outcome by virtual regionalization." Ministry of Health of Ukraine, Children of Chernobyl Relief and Development Fund and Vohnyk Nadii Children's Cardiovascular Surgery and Medical Center Program: "Ukrainian National Forum "Organized Cardio-Surgical Approach to Neonates with Cardiac Birth Defects in the U.S. and Ukraine" Dedication of the National Children's Heart Surgical Hospital, Kyiv, Ukraine (October 2006).
40. Invited Plenary Speaker. "Welcome." Neonatology 2006. 30th Annual International Conference. The Division of Neonatology, Department of Pediatrics, Miller School of Medicine, University of Miami. Miami Beach, FL (November 2006).
41. Invited Plenary Speaker. "International Collaborative Child Health Research." The Basel Life Sciences Mission to Florida: A Partnership for The Future. State of Florida's Enterprise Florida Organization and the University of Miami Miller School of Medicine. Miami, FL (December 2006).
42. Organizer and Plenary Speaker. 1. Speaker "Opening Remarks". 2. Moderator of "Workshop 2: Epidemiology, Etiology, and Outcomes". 3. Speaker "Results from the NHLBI Pediatric Cardiomyopathy Registry." 4. Moderator of "Round Table Discussion 2". 4. Speaker "Consensus recommendations for future areas of epidemiologic and outcomes research in pediatric

- cardiomyopathy.” 5. Moderator of “Young Investigator Presentations” Session. 6. Speaker “Closing Remarks”. The First Pediatric Cardiomyopathy Scientific Workshop entitled “Idiopathic and Primary Cardiomyopathy in Children: Research Directions and Strategies Conference.” Jointly sponsored by the Children’s Cardiomyopathy Foundation the University of Miami Miller School of Medicine and supported in part by grants from the National Heart, Lung and Blood Institute and Genzyme. Bethesda, MD (January 2007).
43. Invited Guest Speaker. “Cardiovascular late effects of therapy for childhood cancer.” Biobehavioral and Cancer Control Symposium. University of Miami Sylvester Comprehensive Cancer Center. Miami, FL (January 2007).
 44. Invited Speaker. “New cardiac biomarkers of cancer therapy related cardiotoxicity.” NCI Investigator Meeting on Late Effects. Boston, MA (February 2007).
 45. Invited Guest Speaker. “Late effects of cancer and its therapy in long term survivors of childhood cancer.” Children’s Cause for Cancer Advocacy, a national patient advocacy nonprofit organization focused on encouraging more rapid development of new therapies in pediatric oncology that are more effective and less toxic and developing programs for childhood cancer patients, survivors and their families to meet the challenges of long-term survivorship. Fourth Annual BeCause We Care reception/fundraiser. Miami Beach, FL (February 2007).
 46. 1. Invited Plenary Speaker. “Preventive Cardiology and Nutrition.” Symposium entitled “Pediatric Nutrition: The Good, The Bad and The Ugly.” 2. Session Moderator. 3. Invited Plenary Speaker. Workshop entitled “The Pediatrician’s Approach to the Child with Complex Congenital Cardiovascular Disease: A Multidisciplinary Team.” 4. Member, Organizing Committee. Masters of Pediatrics Leadership Conferences: Exploring Contemporary and Future Pediatrics. Department of Pediatrics, Miller School of Medicine, University of Miami. Miami Beach, FL (February 2007).
 47. Invited Plenary Speaker. “Cardiovascular Disease in Pediatric Renal Failure.” International Symposium on Pediatric Nephrology. Miami Beach, FL (March 2007).
 48. Invited Plenary Speaker. “Promising clinical indications for NT-proBNP: Assessment of cardiotoxicity.” Fifth proCardio Symposium: NT-proBNP and other biomarkers for the management of cardiac patients. Seville, Spain (May 2007).
 49. Invited Plenary Speaker. “Prevention of cardiotoxicity of Anticancer Agents.” 9th Joint Federation of European Cancer Societies (FECS)/American Society of Clinical Oncology (ASCO)/American Association of Cancer Research (AACR) Workshop on Methods in Clinical Cancer Research. Flims, Switzerland (June 2007).
 50. Invited Plenary Speaker. “Long term follow-up and management of children who have received cardiotoxic treatment”. “Prevention and Management of Cardiotoxicity with Novel Cancer Therapies” Parallel Session 1B at the 20th Anniversary Symposium on Supportive Care in Cancer (SUP-2007). Multinational Association of Supportive Care in Cancer. St. Gallen, Switzerland (June 2007).
 51. Invited Plenary Speaker. “Cardiovascular Effects of ART in Children.” Also Session Moderator and Writing Group Chair for Session III: Vascular Biology: What is known? American Heart Association and the American Academy of HIV Medicine CVD/HIV Advisory Working Group State-of-the-Science Conference: Initiative to Decrease Cardiovascular Risk and Increase Quality of Care for Patients Living with HIV/AIDS. Chicago (June 2007).
 52. Invited Plenary Speaker. “Radiotherapy and cardiovascular outcomes.” Symposium S20 on Cardiovascular Late Effects of Radiation. 13th International Congress of Radiation Research (ICRR). San Francisco, CA (July 2007).
 53. Invited Speaker. “Cardiotoxicity in Childhood Cancer”. NCI DFCI ALL Investigators Symposium. Boston, MA (July 2007).

54. Invited Plenary Speaker and Session Co-Chairman. "State of the Art Presentation: Cardiotoxicity of non-cardiac drugs - Post therapeutic cardiomyopathy." In the Session on "Cardiovascular Effects of 'Non-Cardiac' Diseases." A second Invited Plenary Speaker. "Hypertrophic Cardiomyopathy". Belgian National Foundation for Research in Pediatric Cardiology 15th Anniversary Congress on "The Future of Pediatric Cardiology." Pediatric Cardiology and Cardiac Surgery International Congress Meeting – Scientific Future in Pediatric Cardiology and Cardiac Surgery. Brussels, Belgium (October 2007).
55. Invited Plenary Speaker. "New insights from the US Pediatric Cardiomyopathy Registry" and "Doxorubicin cardiomyopathy: Mechanisms and therapeutic targets." Featured Session on "Cardiomyopathies and Myocarditis." 39th Annual Meeting of the German Society of Pediatric Cardiology. Ulm/Donau, Germany (October 2007).
56. Invited Plenary Speaker. "Preventing Cardiotoxicity in Children." Cardiovascular & Vascular Diseases Session entitled Basic science and clinical research related to the diseases of the vascular system. Tenth Annual Conference on BioFlorida, Inc. Weston, FL (October 2007).
57. Invited Plenary Speaker. "How should cancer patients with cardiac dysfunction be followed and treated?" Special Session SS.11 titled: "Cancer Therapeutics and Cardiotoxicity." American Heart Association Scientific Sessions 2007. Orlando, FL (November 2007).
58. Invited Speaker. "Cardiotoxicity in Cancer Patients." University of Miami Sylvester Comprehensive Cancer Center 15th Annual Scientific Retreat, Marco Island, FL (November 2007).
59. Invited Speaker. "Frequent mitochondrial DNA mutations and polymorphisms in childhood cancer survivors following multi-agent chemotherapy." Third International National Cancer Institute Mitochondria Minisymposium 2008 (NCI MitoMini meeting): Mitochondria and their Proteomics. Bethesda, MD (January 2008).
60. Invited Speaker. "The Impact of Epigenetics (gene-environment interaction) and Development on Pediatric Chronic Illnesses." University of Miami MD-PhD Program Grand Rounds/Chalk Talk. Miami, FL (January 2008)
61. Invited Plenary Speaker. "Cardiac Troponin Evaluation in Oncology." Health and Environmental Sciences Institute (HESI) (a global branch of the International Life Sciences Institute [ILSI]) Technical Committee on The Development and Application of Biomarkers of Toxicity Invitational Workshop on Bridging Preclinical and Clinical Application of Cardiac Troponins as a Tool to Evaluate Drug-Induced Cardiotoxicity. Washington, DC (February 2008).
62. Invited Plenary Speaker and Session Co-Chair. Nutrition Symposium. Masters of Pediatrics Leadership Conferences Exploring Contemporary and Future Pediatrics. Miami Beach, FL (February 2008).
63. Invited Plenary Session Chair. Symposium – Election 2008 – Implications for children's healthcare. United States Congressman Mario Diaz-Balart and Irwin Redlener, M.D. Masters of Pediatrics Leadership Conferences Exploring Contemporary and Future Pediatrics. Miami Beach, FL (February 2008).
64. Invited Workshop Speaker. "Cardiology – Hypertension in the Adolescent, Evaluation and Treatment Session C." Masters of Pediatrics Leadership Conferences Exploring Contemporary and Future Pediatrics. Miami Beach, FL (February 2008)
65. Invited Plenary Speaker. "Cardiac Status of 1- and 2-year-old HIV-1-uninfected children born to HIV-1-infected mothers receiving NRTIs Therapy During Pregnancy." Symposium on Perinatal Exposure to Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Induces Transplacental Genotoxicity and Mitochondrial Toxicity. Society of Toxicology Annual Meeting. Seattle, WA (March 2008).
66. Invited Plenary Speaker. "Pediatric Cardiomyopathy." University of Miami Cardiovascular Research Symposium. NHLBI Training Program in Cardiovascular Signaling. Miami, FL (March 2008).

67. Panel Member. "Cardiovascular Disease and Visions of Interdisciplinary Training, Research and Patient Care." University of Miami Cardiovascular Research Symposium. NHLBI Training Program in Cardiovascular Signaling. Miami, FL (March 2008).
68. Invited Plenary Speaker. "The Future of Pediatric Cardiology – A Chair's Perspective." Pediatric and Congenital Heart Disease Career Session (Leaders of leading pediatric cardiology training programs discuss career opportunities, paths and issues related to clinical therapies, quality initiatives and new approaches to patient care.) Annual Sessions of the American College of Cardiology (ACC.08), Chicago, IL (March 2008).
69. Invited "Keynote Speaker". First Lecture: "Beyond Cholesterol: Reducing Risk for Premature Heart Disease." Second Lecture: "Late Cardiovascular Effects of Childhood Cancer". Annual Pediatric Update. Children's Hospital Medical Center of Akron. Department of Pediatrics, Northeastern Ohio Universities College of Medicine, Akron, Ohio (April 2008).
70. Invited Plenary Speaker. "Raising Healthy Children and Proactive Parents: Connecting the Science to Meaningful Choices for Parents." "Well Being/Being Well-An Integrated Approach to Healthy Living" South Florida Community Educational Conference. University of Miami Sylvester Comprehensive Cancer Center, Miami, FL (April 2008).
71. Invited Plenary Speaker. "Children's Health Services." University of Miami Medical Group Board of Governors Strategic Retreat, Coral Gables, FL (April 2008).
72. Invited Plenary Speaker. First Lecture: "Beyond Cholesterol: Reducing the Risk for Premature Heart Disease." Second Lecture: "Late Cardiovascular Effects of Childhood Cancer". Seventh Annual Pediatric Symposium: A Multispecialty Approach to Pediatric Care. Baptist Children's Hospital, Miami, FL (May 2008).
73. Invited Keynote Speaker. "Childhood Cancer Cardiotoxicity – From Prevention to Late Effects." The Woman's Cancer Association of the University of Miami. 50th Annual Installation & Grant Distribution Luncheon. Coconut Grove, FL (May 2008).
74. Invited Plenary Speaker. "Chemotherapy-associated cardiotoxicity." Session 4A: Clinical Science of Pediatric Heart Failure: Evidence-Based Treatment of Acute Heart Failure. American Heart Association and National Institutes of Health Conference: The Scientific Basis of Heart Failure in Children. Estes Park, CO (May 2008).
75. Education Session Speaker. "Monitoring Methods and Standards for Cardiac Dysfunction." Session S504 title: Prevention and Screening of Treatment Related Cardiac Abnormalities in Survivors of Childhood Cancer. 44th Annual Meeting American Society of Clinical Oncology (ASCO), Chicago, IL (May 2008).
76. Invited Plenary Speaker. First Presentation is part of the Scientific and Medical Sessions: "The Power of Patient Registries for Rare Diseases: Experiences from the Pediatric Cardiomyopathy Registry and their Relevance to Patients with Barth Syndrome and their families." The second Presentation is part of the Family Sessions Panel on "Cardiac Aspects of Barth Syndrome". Dr. Lipshultz was a Speaker and Panel Member for this Family Session and the title of his second talk was the same but modified for families: "The Power of Patient Registries for Rare Diseases: Experiences from the Pediatric Cardiomyopathy Registry and their Relevance to Patients with Barth Syndrome and their families." "Barth Syndrome: On Track Toward a Cure. Fourth International Scientific, Medical and Family Conference." Barth Syndrome Foundation (www.barthsyndrome.org), Clearwater, FL (July 2008).
77. Invited Plenary Speaker. "Prevention of cardiovascular morbidity and mortality in children with chronic kidney failure." Session B on Prevention in the Pediatric Patient. Seventh Annual Conference on Prevention in Renal Disease – Nephrovention 2008. Toronto, Canada (September 2008).
78. Invited Speaker, "Preclinical academic view." Session entitled: "Cardiotoxicity and troponin: where do they fit in drug development." Cardiac Safety Research Consortium (CSRC), the Health and

- Environmental Sciences Institute (HESI), and the U.S. FDA: Cardiac Safety “Hot Topics” Thinktank Annual Meeting 2008 entitled: “Integrating Pre-Clinical and Clinical Issues in Cardiac Safety: Translational Medicine Meets the Critical Path.” (To provide an open think-tank forum integrating pre-clinical and clinical challenges of cardiac safety evaluation of new medical therapeutics). Bethesda, MD (October 2008)
79. Speaker and Chair, “Current Status of the Pediatric Cardiomyopathy Registry”. NHLBI PCMR National Investigator Meeting. Boston, MA (October 2008).
 80. Speaker and Chair, “CHAART Systolic Function Analyses.” NHLBI CHAART-1 Study National Investigator Meeting. Bethesda, MD (October 2008).
 81. Invited Speaker, “The Florida National Children’s Study Center.” National Children’s Study Federal Advisory Committee 20th Meeting and NICHD National Children’s Study Investigator Meeting. Gaithersburg, MD (November 2008).
(<http://www.nationalchildrensstudy.gov/about/organization/advisorycommittee/2008Nov/Pages/NCSA-C-Summary-Minutes-November2008.pdf>).
 82. Invited Plenary Speaker. 32nd Annual Neonatal International Symposium – Neonatology 2008. University of Miami, Miami Beach (November 2008)
 83. Speaker and Chair, “Current Status and Future Directions of the NHLBI PCMR Study.” National Investigator Meeting of the NHLBI PCMR Study. New Orleans, LA (November 2008).
 84. Invited Speaker. “Cardiac Problems in Children Born to HIV-infected Mothers: The ART Effect.” NICHD PHACS Study Semi-Annual Meeting. Bethesda, MD (November 2008).
 85. Speaker and Organizer, “The Importance of Child Health Research.” The University of Miami Micah Batchelor Award Dinner. Miami, FL (November 2008).
 86. Invited Speaker. “Pediatric HIV and Atherosclerotic Risk”. NIH-NHLBI Conference on Mechanisms and Management of Cardiovascular and Metabolic Complications of HIV/AIDS. Bethesda, MD (November 2008).
 87. Invited Pediatric Grand Rounds Speaker. “Late Cardiotoxicity after Childhood Cancer.” Robert Wood Johnson Medical School. University of Medicine and Dentistry of New Jersey. New Brunswick, New Jersey. (December 2008).
 88. Invited Pediatric Grand Rounds Speaker. “Beyond Cholesterol: Reducing Risk for Premature Heart Disease.” University of South Florida School of Medicine, Tampa General Hospital, Tampa Florida. (December 2008).
 89. Invited Pediatric Grand Rounds Speaker. “Late Cardiovascular Effects of Childhood Cancer”. All Children’s Hospital, Saint Petersburg, Florida. (December 2008).
 90. Invited Speaker. “Anthracycline Related Cardiotoxicity.” Pediatric Oncology Branch Research Seminar. Center for Cancer Research. National Cancer Institute. National Institutes of Health, Bethesda, MD (January 2009).
 91. Invited Speaker. “Cardiotoxicity in Cancer.” Cardiology Branch. National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD (January 2009).
 92. Invited Speaker and Session Chair. 1. Co-Moderator Sunday Workshop entitled “Preventive Pediatric Cardiology – State of the Art for General Pediatric Care.” 2. Speaker “Energy Drinks for Children – Are they safe? Should they be banned? What is the current raging controversy?” 3. Co-Moderator Hot Topic Point/Counterpoint Session. 4. Speaker: “Obtaining an echocardiogram for a pediatrician’s concern about cardiovascular disease does not need a cardiology consult vs. every echocardiogram for a pediatrician’s concern about cardiovascular disease should have a cardiology consult.” 5. Co-Moderator: Plenary Session. 6. Meet the Professor speaker. 7. Organizer, Cardiology Track for Masters in Pediatrics University of Miami Masters of Pediatrics Conference. Miami Beach, FL (January 2009).

93. Invited Plenary Speaker. "Cardiac Evaluation of the Child with Chronic Kidney Disease." Thirty-sixth Pediatric Nephrology Seminar. University of Miami Miller School of Medicine. Miami Beach, FL (February 2009).
94. Invited Co-Chair. Educational Session (ACC.Symposium #0601) entitled "HIV-Associated Cardiovascular Disease", American College of Cardiology 58th Annual Scientific Session, Orlando, FL (March 29, 2009).
95. Invited Plenary Speaker. "Antiretroviral Cardiac Disease in Children." Educational Session (ACC.Symposium #0601) entitled "HIV-Associated Cardiovascular Disease", American College of Cardiology 58th Annual Scientific Session, Orlando, FL (March 29, 2009).
96. Invited Co-Chair. Educational Session (ACC.Symposium #0675) entitled "Mechanisms, Monitoring and Treatment of Chemotherapy-Related Heart Failure", American College of Cardiology 58th Annual Scientific Session, Orlando, FL (March 31, 2009).
97. Invited Plenary Speaker. "Beyond Cholesterol: Reducing Risk for Premature Heart Disease." Pediatric Grand Rounds. Chris Evert Children's Hospital, Broward Health System, Fort Lauderdale, FL (April 2009).
98. Invited Speaker and Co-chair. First talk is in the Specialty Meeting entitled "Paediatric Cardiomyopathy" and the title of the talk is "What have we learned from registries – PCMR". Second talk is in the Specialty Meeting entitled "Paediatric Cardiomyopathy" and the title of the talk is "Anthracycline Cardiomyopathy." Fifth World Congress of Paediatric Cardiology and Cardiac Surgery. Cairns, Australia (June 21-26, 2009).
99. Invited Participant. 2009 Cardiology & Oncology Partnership: Cardio-oncology 2009 Conference. Milan, Italy (September 2009).
100. Invited Speaker. Research Presentation: "Cardiovascular abnormalities of children born to HIV-infected women: the role of antiretroviral therapy." NIH Conference on Mechanisms and Management of Cardiovascular and Metabolic Complications of HIV/AIDS. Rosemont, IL (September 2009).
101. Invited Plenary Speaker. Two talks. The first is the Robert Freedom Lecture entitled "Late Cardiovascular Effects of Childhood Cancer. A second talk is entitled "What have we learned from the Paediatric Cardiomyopathy Registry?" The Fourth Toronto 2009 Symposium in Pediatric Cardiology entitled: "Contemporary Questions in Congenital Heart Disease: Heart Failure and Transplantation." The Hospital for Sick Children, Toronto, CA (October 2009).
102. Invited Plenary Speaker. "Cardiovascular Disease Risk Assessment and Diagnosis in HIV Infection." American Heart Association Initiative to Decreased Cardiovascular Risk and Increase Quality of Care for Patients Living with HIV/AIDS Conference. Miami, FL (October 2009).
103. Invited Plenary Speaker. Talk #1 to Pediatric Oncology and others at the Hospital for Sick Children, Toronto, Ontario entitled "Radiation-associated Cardiovascular Toxicity." Talk #2 to the Labatt Children's Heart Center, Hospital for Sick Children, Toronto, Ontario entitled "Beyond Cholesterol: Reducing Risk for Premature Heart Disease." Talk # 3 Hospital for Sick Children's The Pediatric Oncology Society of Ontario Lecture entitled "Cardiotoxicity After Childhood Cancer: Beginning with The End in Mind." Talk #4 Department of Pediatrics Grand Rounds. McMaster University, Hamilton, Ontario. The Pediatric Oncology Society of Ontario Lecture entitled "Cardiotoxicity After Childhood Cancer: Beginning with The End in Mind." (January 2010).
104. Invited Seminar Speaker and Roundtable Participant. "Cardiovascular Safety Pharmacology in Childhood Cancer." Roche Corporation. Nutley, New Jersey. (April 7-8, 2010).
105. Invited Plenary Speaker. "Diagnosis and Management of Cardiomyopathies in Children." University of California San Diego/Rady Children's Hospital Symposium entitled, "Evolving Concepts in the Management of Congenital Heart Disease." San Diego, California. (January 2010).

106. Invited Plenary Speaker. "Beginning with the End in Mind – Avoiding Late Effects after Childhood Cancer." Annual Women's Cancer Assoc Education Day. Miami. (February 2010).
107. Invited Plenary Speaker. "Beyond Cholesterol: Reducing the Risk for Premature Heart Disease" (Wednesday, March 3, 2010) and "Late Cardiovascular Effects of Childhood Cancer" (Tuesday, March 2, 2010). Roundtable Discussant on 1. Cultural Diversity and Health Care Decisions (3/2/10) and 2. Childhood Obesity (3/3/10). Hadassah Medical Organization "From Concept to Cure – A national physicians' council program." Jerusalem, Israel (March 1-5, 2010).
108. Invited Speaker. "Cancer Survivorship-Hope and Cure." The Leukemia and Lymphoma Society Team in Training Program. Miami-Dade College. Kendall, FL. (March 20, 2010).
109. Invited Plenary Session Speaker. "Adverse Events from in utero ART Exposures." NIH Pediatric HIV/AIDS Cohort Study (PHACS) Semi-annual Meeting. Bethesda MD. April 22-23, 2010).
110. Invited Plenary Speaker and Organizer. "Pediatric Cardiomyopathy Registry". Second International Conference on Pediatric Cardiomyopathy. NHLBI and Children's Cardiomyopathy Foundation, Bethesda, MD (May 13 and 14, 2010).
111. Invited Plenary Speaker "Cardiotoxicity in Childhood Cancer Survivors". Emerging Issues in Pediatric Cancer Epidemiology. In the session entitled "Molecular epidemiology research in pediatric cancer epidemiology and late effects." Texas Children's Cancer Ctr, Baylor Coll of Med, Houston, TX (May 13 and 14, 2010).
112. Invited Keynote Speaker. "Beginning with the End in Mind: Cardiotoxicity after Childhood Cancer." Univ of Miami Cardiovascular Research Symp. Miami. (6/11/2010).
113. Invited Plenary Speaker. Friedreich's Ataxia Research Alliance (FARA) Second Cardiac Summit. Children's Hospital of Philadelphia, Philadelphia, PA (June 11, 2010).
114. Invited Plenary Speaker, "Global Burden of Cardiomyopathy." Session 5761 "Global Burden of CVD: part 2". World Congress of Cardiology Scientific Sessions 2010, Beijing, China (June 19, 2010 – 16:00-17:30, Rio Grande, Level 3-306A&B, 16:22).
115. Invited Session Chair, Co-organizer, and Plenary Speaker. Track 4: Anti Cancer Drug Discovery and Development. Third World Cancer Congress (WCC): Health Science without Borders (BIT Life Sciences). Singapore. (June 22-25, 2010).
116. Invited Plenary Speaker, 2010 International Scientific, Medical and Family Conference. Barth Syndrome Foundation Annual Meeting. Orlando, FL (July 26-31, 2010).
117. Invited Plenary Speaker. "Developmental Pathophysiology of CVD" in Session "Mechanisms of Cardiovascular Risk Arising from SDB and Short Sleep" in NHLBI Workshop "Pediatric Sleep Disturbances and Their Contribution to Developmental Pathophysiology of Cardiometabolic Risk." NHLBI, Bethesda, MD. (September 9, 2010).
118. Invited Plenary Speaker. 2010 Third Annual Riley Heart Center Symposium on Cardiac Development entitled "Cardiomyocyte injury and protection", Riley Heart Research Center, Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN. (September 12-14, 2010).
119. Invited lecturer. University of Miami Cardiovascular Pharmacology Course (MCP 632). September 27, 2010 (Monday) on "Pharmacology of Congenital Heart Defects." October 4, 2010 (Monday) on "Cardiomyopathies and Pharmacological Interventions." Both lectures were followed by a paper review by a student on the discussed topic on September 29, 2010 and October 6, 2010 from 9-10:30 in RMSB 6113. (Dr. Danuta Szczesna-coordinator).
120. Invited Visiting Professor. 1. Pediatric Grand Rounds: "Cardiotoxicity after Childhood Cancer." Connecticut Children's Medical Center and 2. Cardiology Grand Rounds: "Cardiomyopathies in Childhood." University of Connecticut Health Ctr., Hartford, CT (October 12, 2010).

121. Invited Plenary Speaker. "Pediatric Cardiovascular Disease Prevention." Cardiometabolic Syndrome in Children. And Member of Diabetes Panel Discussion. 2010 Cardiometabolic Health Congress (CMHC). Boston, MA. (October 20-23, 2010-10/22-11:00 for 20 minutes, Diabetes Panel Discussion-11:20-12:15).
122. Invited Adult Cardiology Grand Rounds Speaker "Beyond Cholesterol: Pediatric Cardiovascular Disease Prevention." University of Miami Hospital. (November 2010).
123. Invited Plenary Speaker. "Setting-up a Pediatric Cardiomyopathy Registry." Japanese Society for Pediatric Cardiology and Cardiac Surgery Annual Meeting. Session on Pediatric Cardiomyopathies. Tokyo, Japan. (November 6, 2010).
124. Visiting Professor Lecture. "Cardiomyopathy after Childhood Cancer." Tokyo Women's Medical University. Tokyo, Japan. (November 8, 2010).
125. Invited Plenary Speaker. "Cardiomyopathy Following Treatment of Childhood Cancer." Cardiovascular Seminar CVS.307 entitled "Cardiomyopathies 2010: Looking Beyond the Sarcomere." November 16, 2010 (Tuesday) 5:30 PM – 6:45 PM. Presentation time 6:15 PM – 6:30 PM. Room E451a. American Heart Association Scientific Sessions 2010, Chicago, IL (November 13-17, 2010).
126. Invited Plenary Speaker. "Radiation-induced cardiovascular injury compared to chemotherapy-induced cardiac toxicity." Session on "Functional and Clinical Studies in Humans". Exploratory Workshop on Radiation-Induced Vascular Effects Resulting from Low Dose Exposure-a Consensus Conference. European Commission-funded Network of Excellence DoReMi. Le Fief des Epoisses, Bombon, France (December 6-10, 2010).
127. Invited Visiting Professor. Pediatric Grand Rounds: "Cardiotoxicity with Childhood Cancer." City of Hope Comprehensive Cancer Center, Duarte, California. (December 16-18, 2010).
128. Invited Grand Rounds Speaker. "Cardiotoxicity with Childhood Cancer." Department of Molecular and Cellular Pharmacology. University of Miami Miller School of Medicine, Miami, FL. (January 18, 2011).
129. Invited Plenary Speaker. "Ongoing Trials-Cardiomyopathy Registry." Muscular Dystrophy Association Duchenne Muscular Dystrophy Research Network Workshop: The Heart in Duchenne Muscular Dystrophy. Center for Gene Therapy, The Research Institute, Nationwide Children's Hospital. Columbus, Ohio. (January 21-22, 2011).
130. Invited Pediatric Grand Rounds Speaker. "Cardiotoxicity with Childhood Cancer." Department of Pediatrics. Yale School of Medicine. New Haven, CT (January 24, 2011).
131. Invited Speaker. "Philanthropy in Pediatric Departments." Association of Medical School Pediatric Department Chairs, Inc. Annual Meeting. San Diego, CA. (March 5, 2011).
132. Invited Speaker. "Introductory Comments". 38th Pediatric Nephrology Seminar. Department of Pediatrics, University of Miami Miller School of Medicine. Miami Beach, FL (March 10-13, 2011).
133. Invited Plenary Speaker. "Childhood Cancer Cardiotoxicity." Second Annual Mary Allen Engle Visiting Lecturer and Visiting Professor. Department of Pediatrics, Joan and Sanford I. Weill Cornell University Medical College and New York-Presbyterian Phyllis and David Komansky Center for Children's Health.
134. Invited Plenary Speaker. "Childhood Cancer Cardiotoxicity." Albert Dorfman, MD, PhD, Distinguished Lecturer. Annual Pediatric Research Day, Department of Pediatrics, University of Chicago, Comer Children's Hospital, Chicago, IL. (June 2, 2011).
135. Invited Plenary Speaker. "Comparison of Late Cardiovascular Risk After Radiation Exposure and After Treatment with Anti-Cancer Drugs. CARDIORISK (The Mechanisms of Cardiovascular Risk After Low Radiation Doses) Symposium. European Commission. Siemens Forum, Munich, Germany (June 7, 2011).

136. Invited Speaker and Roundtable Participant. ILSI Health and Environmental Sciences Institute (HESI) Technical Committee on Cardiac Safety. 2011 Annual Plenary Session. Panel Discussion – “Where are there opportunities to reduce cardiovascular related attrition and improve cardiovascular safety? Joint HESI and CSRC Leadership. Alexandria, VA. (June 29-30, 2011).
137. Invited Plenary Speaker and Cardiac Fibrosis Section Leader. “Cardiac Fibrosis – Current State and Future Perspectives.” Global Fibrosis Meeting. Hoffman-La Roche Corp. Nutley, NJ (August 15-16, 2011).
138. Invited Speaker. AHRQ ACTION II Investigator Consortium Annual Meeting, Bethesda, MD. (September 18, 2011).
139. Invited Plenary Speaker. “Biomarkers in Pediatric Cardiomyopathy.” Pediatric Grand Rounds. Department of Pediatrics, College of Physicians and Surgeons, Columbia University, New York, NY. (September 2011).
140. Invited Plenary Speaker. Symposium about Cardiotoxicity (Cardio-oncology in Pediatrics). Brazilian Pediatric Oncology Congress. Natal, Brazil. (April 2012).

(110902)